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Observational studies and randomized trials have shown that maternal folic acid 
supplementation before and during early pregnancy decreases the risk of neural tube 
defects in offspring. Hence, women of fertile age are advised to use folic acid 
supplements before and during early pregnancy, and food fortification programs with 
folic acid have been introduced in many countries. 
There is concern about the safety of folic acid supplementation in relation to cancer 
risk. However, despite this concern, previous studies on cancer are inconsistent and 
the association between folic acid and cancer is weak.   
Norway and many other countries have information campaigns to increase 
periconceptional folic acid use among women planning pregnancy. Studies have 
shown an association between maternal social and demographic characteristics and 
maternal periconceptional folic acid use. However, little is known whether there is an 
association between social and demographic characteristic of the woman’s partner 
and her folic acid use in the periconceptional period. 
Objectives: 
To investigate the cancer risk (in total and for specific sites) for the mother after folic 
acid supplementation before and/or during pregnancy. 
To investigate the overall risk for childhood cancer and for major childhood cancer 
types after in utero exposure to maternal supplemental folic acid.  
To investigate if selected paternal characteristics are associated with maternal use of 
folic acid in pregnancy.  
Material and methods:  
All live-born children in Norway during 1999–2010, as well as their mothers and 
fathers, were identified by the Medical Birth Registry of Norway and defined as the 
study populations (687,406 children, 429,004 mothers, 434,686 fathers, and 683,785 
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childbirths). We identified maternal and childhood cancer cases by linkage to the 
Cancer Registry of Norway, with follow-up until a cancer diagnosis, emigration, 
death, or the end of 2010. The study population was also linked to the National 
Registry, the Norwegian National Education Database, and the Norwegian Labour 
and Welfare Administration.  
Cancer risk among women using folic acid supplements prior to and during one and 
two or more pregnancies were compared to cancer risk in women not using such 
supplements. Cancer risk in children exposed in utero to maternal folic acid and/or 
multivitamin supplements were compared to cancer risk in children whose mothers 
never used supplements. The associations between folic acid use and cancer risks 
were estimated as hazard ratios (HRs) with 95% confidence intervals (CIs) using Cox 
proportional hazard regression models. The association between recommended 
maternal folic acid use (before and during pregnancy) and paternal age, education, 
occupation, and country of origin was estimated as relative risks (RRs) with 95% CIs 
using log-binomial regression with robust error variances. 
Results:   
From 1999 through 2010, 3,781 mothers developed cancer. The mothers were 
followed for an average of 7 years (range 0.04–12 years), constituting 2,933,587 
person-years. No increased risk was seen for total cancer among women using folic 
acid in one (HR 1.08; 95% CI 1.00–1.18) or two or more pregnancies (HR 1.06; 95% 
CI 0.91–1.22) (pTrend = 0.12). No specific subtypes of cancer showed increased risk. 
Altogether, 799 children developed cancer during follow-up. The mean follow-up 
time was 6 years (range 0.04–12 years), constituting 4,052,679 person-years. We 
found no association between any supplemental folic acid levels and risk of leukemia 
(e.g., high-level folic acid HR 1.25; 95% CI 0.89–1.76, pTrend 0.20), lymphoma (HR 
0.96; 95% CI 0.42–2.21, pTrend 0.51), central nervous system tumors (HR 0.68; 95% 
CI 0.42–1.10, pTrend 0.32), neuroblastoma (HR 1.05; 95% CI 0.53–2.06, pTrend 0.85), 
Wilms’ tumor (HR 1.16; 95% CI 0.52–2.58, pTrend 0.76), or soft-tissue tumors (HR 
0.77; 95% CI 0.34–1.75, pTrend 0.90). 
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During 1999–2010, the mothers used folic acid supplements before and during 
pregnancy, as recommended, in about 16% of all births in the study population. 
Recommended maternal folic acid use was low among mothers whose partners were 
young (e.g., <20 years RR 0.35; 95% CI 0.28–0.43) or older (e.g., ≥ 40 years RR 
0.72; 95% CI 0.71–0.74), had attained a lower educational level (RR 0.69; 95% CI 
0.68–0.71), fitted the occupational classes other than “Higher professionals,” and 
originated from low/middle-income countries (RR 0.58; 95% CI 0.56–0.60). 
Conclusion:   
There was no association between folic acid supplementation before and/or during 
pregnancy and short-term risk of maternal and childhood cancer. A longer 
observation of our study population may have increased the statistical power of our 
analyses.  
Despite official recommendations and information campaigns aimed at fertile women 
in Norway, periconceptional folic acid supplementation is insufficient. Our study 
demonstrates that recommended periconceptional folic acid use was lower when 
fathers were among the youngest and oldest, had shorter education, were self-
employed or worked in manual occupations, or originated from low/middle-income 
countries. 
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ICD-7   International Classification of Diseases, seventh revision 
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NTD   Neural tube defects 
RR   Relative risk 
REK Regional Committee for Medical and Health Research Ethics of 
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 14
Summary 
 What is already known What is added by this study 
Publication I Randomized and observational 
studies have shown that maternal 
periconceptional folic acid 
supplement use reduces the risk of 
neural tube defects in the fetus 
and protects against some 
neurodevelopmental disorders and 
pregnancy complications. 
However, there is still concern 
about the safety of folic acid 
supplementation in relation to 
cancer risk.  
Folic acid supplementation before 
and during pregnancy does not 
increase the short-term overall 
maternal cancer risk. Folic acid 
use in one (HR 1.08; 95% CI 
1.00–1.18) or two or more 
pregnancies (HR 1.06; 95% CI 
0.91–1.22) (pTrend= 0.12) was not 
associated with increased overall 
cancer risk. Examination of 13 
different cancer types revealed no 
associations between folic acid 
and cancer. 
Publication II Several case-control studies and 
an international collaborative 
study have shown reduced risk of 
acute lymphoblastic leukemia and 
acute myeloid leukemia in 
offspring, and of brain tumors 
among children exposed to 
maternal folic acid use. Ecological 
studies from Canada and the US 
have shown reduced incidence of 
Wilms’ tumor, primitive 
neuroectodermal tumors, and 
neuroblastoma following 
Folic acid supplementation was 
not related to short-term risk of 
major childhood cancers. Folic 
acid was not associated with 
leukemia (HR 1.25; 95% CI 0.89–
1.76, pTrend 0.20), lymphoma (HR 
0.96; 95% CI 0.42–2.21, pTrend 
0.51), central nervous system 
tumors (HR 0.68; 95% CI 0.42–
1.10, pTrend 0.32), neuroblastoma 
(HR 1.05; 95% CI 0.53–2.06, 
pTrend 0.85), Wilms’ tumor (HR 
1.16; 95% CI 0.52–2.58, pTrend 
0.76), or soft-tissue tumors (HR 
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mandatory folic acid flour 
fortification. 
0.77; 95% CI 0.34–1.75, pTrend 
0.90). 
Publication III Maternal predictors of folic acid 
supplementation are; low maternal 
age, shorter education, single 
parenthood, unplanned pregnancy, 
lower parity, smoking, alcohol 
use, less physical activity, or 
originating from a foreign 
country. However, only a limited 
number of studies have identified 
paternal determinants for maternal 
folic acid intake before and during 
pregnancy. 
Adequate maternal 
periconceptional folic acid 
supplementation was lower if the 
fathers were younger [e.g. < 20 
years (RR 0.35; 95% CI 0.28–
0.43)], or older than 30–34 years 
[≥ 40 years (RR 0.72; 95% CI 
0.71–0.74)], had shorter education 
(RR 0.69; 95% CI 0.68–0.71), 
held manual or self-employed 
occupations [e.g. class VI Skilled 
(RR 0.84; 95% CI 0.83–0.86) or 
class VII Semiskilled and 
unskilled (RR 0.75; 95% CI 0.73–
0.76)], or were born in 
low/middle-income countries (RR 





The name folate is derived from the Latin word “folium”, which means large-leafed 
plant. Humans cannot synthesize folates, and they have to be supplied through the 
diet. Folate (vitamin B9) is an essential water-soluble vitamin naturally present in 
leafy vegetables and some fruits. It is essential for nucleotide biosynthesis, DNA 
replication, and methyl group supply, and consequently for cell growth and repair 
(Bailey et al. 2015). Furthermore, folate is involved in the homocysteine metabolism 
and helps maintain normal levels of this amino acid. Food folates are absorbed in the 
jejunum and transported to the liver, which contains about 50% of body pool folate 
(Ohrvik and Witthoft 2011). Inadequate folate intake leads to decreased serum folate, 
then decreased erythrocyte folate, a rise in homocysteine levels, and megaloblastic 
changes in the bone marrow (Bailey et al. 2015). Thus, folate deficiency may cause 
various health problems, such as hyperhomocysteinemia, megaloblastic anemia, and 
neurological disorders (Bailey et al. 2015, Reynolds 2014).  
Folate requirements increase during pregnancy. Several studies report higher folate 
status (as defined by various measures including blood folate concentrations, folate 
intake, and/or folic acid intake) before and during early pregnancy than in late 
pregnancy and after (Cikot et al. 2001, Milman et al. 2006). Short interpregnancy 
intervals may play a role in preconception folic acid use due to maternal nutrient 
depletion, and the maternal folate status is likely to worsen with short intervals 
between multiple pregnancies (Nilsen et al. 2014, van Eijsden et al. 2008). 
The role of folate in pregnancy was first reported in 1964 by Brian Hibbard (Hibbard 
1964), who performed a study of folate status as urinary excretion of 
formiminoglutamic acid (FIGLU) in 1,484 low-income obstetric patients from 
Liverpool, United Kingdom. Hibbard found that abnormal FIGLU excretion was not 
only related to megaloblastic anemia, placental abruption and spontaneous abortion, 
but also to premature births, congenital defects and perinatal mortality in previous 
pregnancies. Thereafter, Hibbard and Smithells proposed that folate deficiency in 
pregnancy may be associated with central nervous system malformations (Hibbard 
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and Smithells 1965). This was eventually confirmed in the 1990s by randomized 
intervention trials (Botto et al. 1999, van der Put et al. 2001). 
A large body of evidence from clinical trials and observational studies shows that 
improving periconceptional folate status before and during early pregnancy can 
reduce the risk of neural tube defects (NTDs) (Berry et al. 1999, Czeizel and Dudas 
1992, Medical Research Council Vitamin Study 1991, Milunsky et al. 1989). Thus, 
increased folic acid (synthetic form of folate) intake before and during the first three 
months of pregnancy is recommended in several countries, including Norway 
(National Council on Nutrition and Physical Activity 1998, Nordic Council of 
Ministers 2014, Scientific Advisory Committee on Nutrition 2006, U.S. Department 
of Health and Human Services 1992).  
Previous studies have shown that folic acid supplementation is associated with a 
lower risk of other neurodevelopmental disorders and some severe pregnancy 
complications like placental abruption, risk of autism spectrum disorders in children, 
and severe language delay in children (Nilsen et al. 2008, Roth et al. 2011, Suren et 
al. 2013).  However, periconceptional folic acid use is not associatiated with severe 
congenital heart defects or isolated oral clefts (inverse association between 
periconceptional folic acid use and oral clefts in combinations with other 
malformations) (Gildestad et al. 2015, Leirgul et al. 2015), and there is still 
inconclusive evidence of an association between congenital urinary tract and genital 
anomalies and folic acid use (Bortolus et al. 2014). 
NTDs occur during early embryonic development when the neural tube fails to close 
completely between 21 and 28 days after conception (Sadler and Thomas 2015). In 
Norway, the Norwegian Directorate of Health recommends that all women who are 
planning pregnancy or who are likely to become pregnant should take 0.4 mg of folic 
acid daily from one month before pregnancy throughout the first 2–3 months of 
pregnancy (National Council on Nutrition and Physical Activity 1998). 
In Norway, the dietary intake of folate alone is not sufficient with regard to 
minimizing the risk of NTDs (Daltveit et al. 2004, Nilsen et al. 2014). The average 
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folate intake from foods in Norway is lower than 0.3 mg per day across the overall 
Norwegian population (Sengpiel et al. 2013). 
Numerous countries worldwide have performed campaigns to increase 
periconceptional supplementation of folic acid among fertile women to reduce the 
risk of NTDs (National Council on Nutrition and Physical Activity 1998, Nordic 
Council of Ministers 2014, U.S. Department of Health and Human Services 1992). 
However, it seems that women tend to start supplementation too late to prevent NTDs 
(Bitzer et al. 2013, Eichholzer et al. 2006, Nilsen et al. 2006), possibly due to 
unplanned pregnancies. In order to ensure adequate folate intake among fertile 
women, several countries, including the US and Canada, have also introduced 
mandatory food fortification with folic acid (European Food Safety Authority [EFSA] 
2009, Food and Drug Administration 1996). In these countries, a reduced risk of 
neural tube defects has been reported (Castillo-Lancellotti et al. 2013). However, 
folic acid fortification has been implemented in Moldova and Kosovo (Wald et al. 
2018) but not in other European countries including Norway, due to concerns 
regarding folic acid’s potential role in cancer development (European Food Safety 
Authority [EFSA] 2009). 
1.1 Folic acid 
The synthetic form of folate is folic acid (pteroyl monoglutamic acid), which is the 
fully oxidized form of folate. In contrast to folate, folic acid is chemically stable 
without loss of biochemical activity for months, rendering it very resistant to 
chemical oxidation (Bailey et al. 2015). Folic acid is used commercially in 
supplements and fortified foods (Pietrzik et al. 2010), and it has substantially higher 
bioavailability relative to food folate. 
Figure 1 shows the proposed mechanism of folic acid absorption and transportation 
through the mucosa. The human gut has limited ability to reduce folic acid to 5-
methyl tetrahydrofolate (Patanwala et al. 2014). Therefore, a large amount of 
unaltered folic acid enters the circulation and is taken up by the cells in the liver, 
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where it is subsequently transformed to tetrahydrofolate, and further to 5-methyl-
tetrahydrofolate, by enzymatic processes (Figure 2) (Bailey et al. 2015, Nazki et al. 
2014, Patanwala et al. 2014).  
Depending on the dose, some folic acid is transported unmetabolized to the peripheral 
circulation. In contrast to folate, folic acid needs to be reduced to tetrahydrofolate via 
dihydrofolate by dihydrofolate reductase. The initial step is slow and may be 
influenced by individual variations in dihydrofolate reductase activity (Bailey et al. 
2015).  
 
Figure 1: Proposed folate absorption from the gut lumen, metabolism in 
mucosal cells, and transport out into the hepatic portal vein. DHFR, 
dihydrofolate reductase; PCFT, proton-coupled folate transporter; THF, 
tetrahydrofolate; 5-MTHF, 5-methyltetrahydrofolate. Adapted from 




Figure 2: Folic acid metabolism: DHFR, dihydrofolate reductase; SHMT1, 
serine hydroxymethyl transferase 1; B6, vitamin B6; MTHFR, 
methylenetetrahydrofolate reductase; B2, vitamin B2; TS, thymidylate 
synthase; MTR, methionine synthase; B12, vitamin B12; MTRR, methionine 
synthase reductase; DHF, dihydrofolate; THF, tetrahydrofolate; 5,10-MTHF, 
5,10-methyltetrahydrofolate; 5-MTHF, 5-methyltetrahydrofolate; dUMP, 
deoxyuridine monophosphate; dTMP, deoxythymidylate monophosphate; 
10-Formyl THF, 10-formyl tetrahydrofolate; SAM, S-adenosylmethionine. 
Adapted from Nazki et al. (2014) with permission  
 
Folate acts as a coenzyme in transferring one-carbon units in the biosynthesis of 
purine nucleotides and deoxythymidylic acid, which is important in the synthesis of 
DNA and RNA. Consequently, folate plays an important role in nucleotide synthesis, 
gene expression and methylation. DNA methylation is essential for cell 
differentiation and embryonic development. Moreover, DNA methylation plays a role 
in mediating gene expression, chromatin structure, chromosome stability and 
inactivation of the X chromosome (Robertson 2005). Folate also remethylates 
homocysteine to methionine, which is the precursor of S-adenosylmethionine, the 
primary methyl group donor for most biological methylations, including DNA 
(Eichholzer et al. 2006, Krishnaswamy and Madhavan Nair 2001, Lucock 2004). 
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The folate status is affected by variations in folate-dependent enzymes. 
Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folic acid 
metabolism and DNA methylation reactions. MTHFR catalyzes the conversion of 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is a cosubstrate 
for the creation of methionine from homocysteine (Trimmer 2013). The MTHFR 
enzyme is encoded by the MTHFR gene (Leclerc et al. 2013). Single-nucleotide 
polymorphisms in MTHFR coding genes may cause the production of an enzyme 
with decreased activity that can have an impact on several biochemical processes. 
Although several MTHFR variants are identified, two polymorphisms have been 
extensively studied: the C-to-T substitution (677C→T polymorphism) that occurs at 
locus 677 of the MTHFR gene (Ueland et al. 2001), and the 1298A→C that occurs at 
locus 1298 (van der Put et al. 1998). Both of these MTHFR polymorphisms (when in 
the homozygous state) are associated with DNA hypomethylation through their 
genotypes; however, this is less pronounced for the 1298CC MTHFR genotype 
(Castro et al. 2004). DNA hypomethylation (commonly seen in solid tumors) as well 
as DNA hypermethylation in the region of tumor suppressor genes are well-
recognised epigenetic changes that occur in human neoplasms (Jones 2005). 
1.2 Folic acid and adult cancer  
The World Health Organization defines cancer as a group of diseases involving 
abnormal cell growth with the potential to invade and metastasize to other parts of the 
body (World Health Organization 2015a). Cancer is a genetic disease resulting from 
corrupted information in the cellular DNA, leading to abnormal gene expressions and 
fundamental changes in biological processes within cancer cells (Hanahan and 
Weinberg 2011, Harrington 2016). Normal genes that control cellular growth, 
survival and invasion are enhanced, and other genes that suppress growth and 
invasion are repressed. The genes involved in cancer are divided into two types: 
oncogenes, and tumor suppressor genes. Activation of oncogenes occurs by specific 
point mutations within a gene, by multiplied copies of this gene, or by translocation 
of the gene to a DNA site with high transcription activity or formation of a fusion 
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gene that codes for proteins with enhanced biological activity (Harrington 2016). This 
causes uncontrolled cell divisions, enhanced cell survival and enhanced 
dissemination. A single copy of this mutated gene (proto-oncogene) is sufficient to 
start cancer disease. Tumor suppressor genes function to inhibit cell proliferation and 
survival by regulating cell divisions and apoptosis. Inactivation of tumor suppressor 
genes occurs by mutations that terminate the function of the protein encoded by the 
gene, or by silencing the promotor of the gene. In contrast to oncogenes, tumor 
suppressor genes are recessive genes – i.e., both copies of the genes must be affected 
in order to promote cancer. Thus, they are responsible for inherited cancer syndromes 
(Harrington 2016). In hereditary cancer syndromes, a germline mutation in one allele 
of a tumor suppressor gene affects every cell in the body, and it is likely that one of 
these cells will lose its tumor suppressor function and may progress to cancer early in 
life (Harrington 2016). 
Cancer behavior is defined in terms of eight specific hallmarks: sustaining 
proliferative signaling, evading growth suppressor, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, 
the capability to modify, or reprogram cellular metabolism, and allow cancer cells to 
evade immunological destruction (Hanahan and Weinberg 2011). 
About 33% of cancers in Western high-income countries are attributable to factors 
associated with food, nutrition and physical activity (Wiseman 2008). The etiology 
for several cancers has been linked to specific environmental factors: e.g. sun 
exposure and skin cancers, human papilloma virus and uterine cervical cancer, 
Helicobacter pylori and gastric cancer, viral hepatitis and hepatocellular cancer, and 
smoking and lung cancer (Wu et al. 2018). Further, there is evidence of a direct 
association between diet, lifestyle and cancer risk (Baena Ruiz and Salinas Hernandez 
2014). Saturated fat intake and alcohol intake seem to increase breast cancer risk 
(Gonzalez and Riboli 2010), and consumption of  red or processed meat cooked at a 
high temperature may be associated with increased colorectal cancer risk (Pericleous 
et al. 2013). Conversely, vitamins C and D, some carotenoids, retinol and α-
tocopherol, and high intake of dietary fiber and fish reduce the risk of gastric and 
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colorectal cancer (Gonzalez and Riboli 2010). Further, there is evidence that intake of 
whole grains, pulses, vegetables and fruits, and low intake of sugary foods, salt, and 
red and processed meats are associated with lower risk of several cancers (mouth, 
pharynx, larynx, lung, esophageal, stomach, pancreas, and colorectal) (Norat et al. 
2015). 
Folate functions as a coenzyme in the one-carbon reactions necessary for purine 
nucleotide synthesis, thymidylate synthesis and remethylation of homocysteine to 
methionine. Disruption in the one-carbon metabolic pathway caused by nutritional 
deficiencies or gene polymorphisms affect DNA synthesis, DNA stability and 
chromatin methylation (Stover 2011). 
Low folate levels in the human body are associated with an ineffective DNA 
synthesis that affects cell proliferation, cellular physiology and cytological 
morphology (Kim 1999). Human tissue experiments have shown that folate 
deficiency causes chromosome breaks that may contribute to increased cancer risk 
(Blount et al. 1997). Another proposed mechanism may be promotion of cancer cells 
through de novo methylation of tumor suppressor genes with consequent gene 
inactivation, which leads to tumor progression (Kim 2006). Animal studies on folate 
and intestinal cancers have shown that inadequate folate intake is an independent risk 
factor for colorectal cancer (Kim 2003). Similar findings of an association between 
low folate intake and risk of colorectal cancer has been suggested in humans. A 
prospective cohort study encompassing 525,488 individuals in the US aged 50–71 
years from 1995–96 with mean follow-up of 9.1 years, showed that higher folate 
intake (> 0.2 mg) was associated with reduced colorectal cancer risk (Gibson et al. 
2011). Conversely, there are other studies reporting either no association between 
folic acid supplementation and colorectal cancer risk (Eussen et al. 2010) or a 
reduced risk of colorectal cancer among individuals with low folate status (Gylling et 
al. 2014, J. E. Lee et al. 2012). However, there is support for a potential protective 
role of folate on colorectal cancer risk. Zacho et al. have performed a cross-sectional 
study of 5,949 adults and a prospective study of 9,235 adults in Denmark, as well as 
meta-analyses of 231 studies including 74,671 cases and 93,344 controls (Zacho et al. 
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2011). They showed that the homozygous MTHFR 677C→T polymorphism (with 
lifelong hyperhomocysteinemia) compared to non-carriers of the polymorphism was 
not associated with overall cancer risk. The homozygous MTHFR 677C→T 
polymorphism was, though, associated with increased risk of esophageal and gastric 
cancer, and with decreased risk of colorectal cancer. On the other hand, a Norwegian 
study based on two randomized, double-blind placebo-controlled clinical trials on a 
total of 6,837 patients (mean age 62.3 years and 23.5% women) with ischemic heart 
disease, showed that patients taking folic acid supplements (0.8 mg/day combined 
with other B vitamins) who also had the homozygous MTHFR 677C→T 
polymorphism, had a greater cancer mortality risk than those who had the 677CC 
genotype (Ebbing et al. 2009). 
To our knowledge, no studies except for the investigation by Charles et al. in 2004, 
have studied the effect of folic acid supplementation in young, mainly healthy women 
of fertile age (Charles et al. 2004). Their finding of increased overall cancer mortality 
and breast cancer mortality among women taking high doses of folic acid (5 mg/day) 
as compared to placebo, was later criticized because the trial was carried out in the 
1960s and did not meet current standards of research, such as double-blind and 
randomized clinical trials (Bland 2005). The authors themselves and the commentary 
by Oakley and Mandel pointed out that the reported associations might just be 
“chance findings” (Oakley and Mandel 2004).  
However, findings from epidemiological studies have been inconsistent regarding 
whether folate poses a cancer risk or not. Two randomized controlled trials (about 
14,000 individuals in total) found no protective nor harmful association between folic 
acid use (in combination with other B vitamins) and cancer risk (overall and site-
specific) (Hankey et al. 2012, Zhang et al. 2008). Furthermore, two meta-analyses on 
folic acid supplementation reported no increased nor decreased incidence of lung 
cancer (4,390 cases and 6,138 controls from six case-control studies) (Dai et al. 
2013), nor overall or site-specific cancer (49,621 participants in 13 randomized trials) 
(Vollset et al. 2013).   
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Finally, there seems to be a complex biological association between folic acid and 
adult cancer that needs cautious interpretation, and further biological and 
epidemiological research is necessary.  
1.3 Folic acid and childhood cancer 
Childhood cancer is defined as cancer diagnosed in an individual aged 14 years or 
younger (before puberty) (Bahadur and Hindmarsh 2000). Childhood and adolescent 
cancers differ from adult cancers in that they are histologically very diverse. Most 
adult cancers are carcinomas (Bahadur and Hindmarsh 2000). Childhood and 
adolescent cancers arise from embryonic cells and originate in developing tissues and 
organ systems. Embryonal malignancies include neuroblastoma, Wilms’ tumor, 
medulloblastoma, rhabdomyosarcoma, and retinoblastoma (International Agency for 
Research on Cancer 2014). Some adolescent cancers are more similar to adult cancers 
– e.g., acute myeloid leukemia, Hodgkin lymphoma, thyroid cancer, and melanoma. 
Childhood cancers are therefore classified according to the third revision of the 1996 
International Classification of Childhood Cancer (ICCC-3) (Steliarova-Foucher et al. 
2005). ICCC-3 applies the rules, nomenclature and codes for morphology, 
topography and behavior according to the International Classification of Diseases for 
Oncology (ICD-O-3), third revision of 2000. Further, ICCC-3 is a three-level 
hierarchical classification system, with 12 main groups, 47 subgroups, and the 16 
most heterogeneous subgroups are split further into 2–11 divisions in order to study 
important entities or homogeneous collections of tumors characterized at cytogenetic 
or molecular level. 
Cancer is rare among children. The age-standardized incidence worldwide during 
2001–10 was 14 per 100,000 person-years at age 0–14 (Steliarova-Foucher et al. 
2017), and in Norway during 2007–16, the incidence was 15 per 100,000 person-
years (National Clinical Registry for Childhood Cancer 2016). 
The etiology of childhood cancers is generally unknown. Familial or genetic factors 
are thought to predispose a child to cancer in 10% of cases (Jongmans et al. 2016). 
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Transplacental exposure to xenobiotics before birth is associated with childhood 
leukemia, neuroblastoma, brain tumors, hepatoblastoma, and Wilms’ tumor through 
induced genomic, epigenomic and/or non-genomic effects (Fucic et al. 2017). Since 
the majority of childhood cancers are diagnosed at an early age, a fetal origin has 
been suspected (Callan and Milne 2009). Furthermore, anthropometric measurements 
at birth show that fetal growth is positively associated with increased risks of 
different childhood cancers, supporting the hypothesis that the tumorigenesis 
manifesting in childhood may start in utero (Bjørge et al. 2013). 
Mutations are relatively rare in childhood cancers, and various candidate-gene or 
genome-wide studies show that epigenetic deregulation plays an essential role in 
childhood cancer development (Yiu and Li 2015). DNA methylation, which is a 
crucial epigenetic mechanism, is dependent on dietary folate metabolism through the 
one-carbon pathway. Fetal exposure to folate during pregnancy affects DNA 
methylation in the offspring during fetal development (Amarasekera et al. 2014), and 
low maternal folate status corresponds to global DNA hypomethylation in fetuses 
diagnosed with NTDs (Chang et al. 2011). However, periconceptional folic acid 
supplementation (0.4 mg/day) is associated with increased methylation at the insulin-
like growth factor 2 gene in children aged 17 months (Steegers-Theunissen et al. 
2009). Other studies also find an association between prenatal folic acid use and 
modified DNA methylation in the child (Fryer et al. 2009, Hoyo et al. 2011).  
Genetic polymorphisms that code the enzymes involved in the folate pathway 
regulate the folate metabolism. A recent meta-analysis of MTHFR polymorphisms 
reported that the C677T (677C→T) polymorphism may be associated with decreased 
risk of ALL (Wang et al. 2012). Protection against childhood cancer through maternal 
folic acid use before and during pregnancy is biologically plausible because folate 
and other B vitamins are essential in maintaining genomic stability through DNA 
methylation, synthesis and repair (Duthie and Hawdon 1998, Kim 1999).  
Ecological studies from Canada and the USA, without individual-level information 
on maternal folic acid intake, have shown reduced incidence of Wilms’ tumor, 
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primitive neuroectodermal tumors, and neuroblastoma among children born after the 
introduction of folic acid food fortification in 1998. No reduction was found in the 
incidence of other childhood cancers after initiation of fortification compared to 
children who were born before fortification was introduced (French et al. 2003, 
Grupp et al. 2011, Linabery et al. 2012).  
In 2001, a case-control study from Western Australia showed reduced risk of 
childhood acute lymphoblastic leukemia (ALL) among children exposed to 
supplements containing folic acid or iron (Thompson et al. 2001). Subsequently, a 
national, population-based, multicenter case-control study performed in Australia 
between 2003 and 2007 conveyed a weak protective association of self-reported 
maternal folic acid supplementation before pregnancy with risk of childhood ALL, 
but no indication of a protective association of folic acid supplementation during 
pregnancy (Milne et al. 2010). A large international collaborative study, including 
6,963 children with ALL, 585 children with acute myeloid leukemia (AML), and 
11,635 controls, found reduced risks of ALL and AML after maternal intake of folic 
acid and other vitamin supplements. The reduced risks of ALL and AML did not vary 
by time of supplementation exposure (preconception, pregnancy, or pregnancy 
trimester) (Metayer et al. 2014). In addition, another national, population-based, 
multicenter case-control study conducted in Australia between 2005 and 2011 
reported that folic acid supplementation before and during pregnancy may protect 
against childhood brain tumors (Milne et al. 2012). However, a population-based 
case-control study of children born in Sweden between 1975 and 1984 (500 cases and 
500 controls) showed no association between maternal use of folic acid supplements 
and other medications with the risk of childhood brain tumors (Stalberg et al. 2010). 
In summary, maternal periconceptional folic acid supplementation seems to be 
associated with reduced risk of childhood leukaemia, childhood brain tumors and 
other childhood cancer types. However, there is concern regarding the safety of folic 
acid in relation to cancer risk and further epidemiological and biological studies may 
be helpful in informing future risk assessments on a possible association between 
folic acid supplementation and childhood cancer risk. 
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1.4 Determinants of periconceptional folic acid use 
Low intake of folate from foods is the main cause of low folate status in humans, 
which is a risk factor of NTDs (Daly et al. 1995, Scientific Advisory Committee on 
Nutrition 2006). Many countries in Europe have performed information campaigns to 
increase periconceptional folic acid supplementation among women planning 
pregnancy (Bower et al. 2005, Daltveit et al. 2004, Staff et al. 2005). In Norway, 
women planning pregnancy are advised to take a daily supplement of 0.4 mg of folic 
acid from one month before pregnancy through the first three months of pregnancy 
(National Council on Nutrition and Physical Activity 1998). However, public health 
campaigns promoting periconceptional folic acid use have been unsuccessful in many 
European countries (European Food Safety Authority [EFSA] 2009).  
Because the neural tube closes between 21 and 28 days after conception, it is 
important to start folic acid supplementation before conception (Sadler and Thomas 
2015). Many European women of childbearing age are unaware that using folic acid 
supplements before and during early pregnancy reduces the risk of NTDs (Bitzer et 
al. 2013). Important predictors of inadequate maternal periconceptional folic acid 
supplementation are unplanned pregnancies, low socioeconomic levels, and young 
maternal age (Eichholzer et al. 2006). Low income, parity of more than one, smoking 
or alcohol use during pregnancy, and a low-income country of origin are also 
associated with low compliance with recommended folic acid use (Bower et al. 2005, 
Braekke and Staff 2003, Cueto et al. 2012, Daltveit et al. 2004, Knudsen et al. 2004, 
Nilsen et al. 2006, Timmermans et al. 2008).  
A Norwegian study with data from 2000–2003 reported that folic acid supplements 
were used more frequently among women who had higher-educated partners (Nilsen 
et al. 2006). However, the association of paternal education with maternal folic acid 
use was weaker than that of maternal education. The study did not assess other 
paternal factors or combine paternal and maternal factors as to identify inadequate 
maternal folic acid supplementation. Still, supportive evidence of this finding is that 
couples tend to exhibit concordant health behaviors for dietary intake, body mass 
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index (BMI), smoking, alcohol consumption and physical activity (Jackson et al. 
2015). Persons living together share the same environment, social network, financial 
resources, and somewhat, the same health risk; beneficial or negative to health 
outcomes depending on the health behavior of the partner (Cornelius et al. 2016, 
Jackson et al. 2015). Moreover, a person within a couple is more likely to make a 
positive health behavior change if their partner does so (Jackson et al. 2015).  
Less is, however, known about how partners may influence the maternal 
periconceptional use of folic acid. Consequently, it is important to investigate how 
the partner of the mother can encourage maternal folic acid use.  
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2. Aim of the thesis 
This thesis is part of a larger project which examines the later health 
consequences for the mother and child after supplemental folic acid in pregnancy.  
The specific aims of this thesis were: 
1. To assess the cancer risk (in total and for specific sites) for the mother after 
folic acid supplementation before and/or during pregnancy. 
2. To assess the overall risk for childhood cancer and for major childhood cancer 
types after maternal supplemental folic acid in pregnancy.  
3. To evaluate if paternal characteristics are associated with maternal 
periconceptional use of folic acid in pregnancy.  
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3. Material and methods 
In this section, the study populations and the sample selection criteria used for each 
publication in the thesis are described. 
3.1 Data sources 
3.1.1 National Registry 
The National Registry of Norway was established in October 1964. It assigns a 
unique personal identification number to all individuals living, born or immigrated to 
Norway since the national census in 1960 (Hammer 2002, Statistics Norway 2017). 
The personal registration number allows a precise linkage between the national 
registries and other databases in Norway. Further, the National Registry contains 
demographic data on all residents in Norway since 1960, such as name, date and 
place of birth, residential address, if the resident is alive, emigrated or dead, 
citizenship, marital status, country immigrated from or emigrated to and several other 
information elements. The Norwegian Tax Administration is responsible for ensuring 
the completeness of the register and keeping the records up to date.  
3.1.2 Medical Birth Registry of Norway 
The Medical Birth Registry of Norway is a national, population-based health registry 
containing information on all births in Norway since 1967. It presently holds 
information on more than 2.8 million births (Norwegian Institute of Public Health 
2017). The registry enables identification of women and all their successive births. It 
holds demographic information on the mother and father, the mother’s health before 
and during pregnancy, including chronic diseases, and complications during 
pregnancy and delivery. In addition, information on the infant, including birth defects 
and other perinatal problems, is included. The data enrolled in the Medical Birth 
Registry of Norway is collected from a notification form that midwives and 
physicians attending the births are entrusted to complete. All pregnancies ending after 
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week 16, including stillbirths, are notifiable and must be reported to the Medical 
Birth Registry of Norway (Irgens 2000, Norwegian Institute of Public Health 2004).  
Since December 1998, a revised version of the notification form has been used, 
including new variables such as maternal dietary supplement intake and whether the 
mother is a smoker or non-smoker (Appendix 1).  
The publications in this thesis were based on data from the revised form only. 
3.1.3 Cancer Registry of Norway 
The Cancer Registry of Norway was established in 1951 and contains mandatory 
reported information on all new cancer cases and certain precancerous lesions in 
Norway (Larsen et al. 2009). Information from clinical notifications, pathological 
notifications and death certificates are the main reporting sources, providing 
information about site, histological type and stage of disease at the time of diagnosis.  
The coding and classification system at the Cancer Registry of Norway follows 
international standards (Larsen et al. 2009). In our dataset the International 
Classification of Diseases version 10 (ICD-10) and the International Classification of 
Childhood Cancer, version 3, which is based on ICD-O-3, has been the basis for 
coding, including topography and morphology codes (Cancer Registry of Norway 
2016, Steliarova-Foucher et al. 2005, World Health Organization 2015b). 
3.1.4 The Norwegian Labour and Welfare Administration 
The Norwegian Labour and Welfare Administration was established in 2006 
(Norwegian Labour and Welfare Administration 2018). The organization holds 
information on employment, health status and social benefits of all individuals with 
residence in Norway since 1992 through the historical event database FD-Trygd 
(Akselsen and Siverstøl 2013). The occupational code system is based on the 
International Standard Classification of Occupations (ISCO), revised version from 
1988 (Statistics Norway 1998).  
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3.1.5 Norwegian National Education Database 
The Norwegian National Education Database holds information on all individuals’ 
educational theory and practice since 1970, from completion of primary school to 
doctoral studies (Vangen 2007). All information on educational attainment is reported 
annually from respective educational institutions to the Norwegian National 
Education Database (Government of Norway 1998). The database is also a register of 
the population’s highest completed level of education (Statistics Norway 2013, 
Vangen 2007). The classification is based on a 6-digit coding system of the 
Norwegian Standard Classification of Education (Statistics Norway 2013, Statistics 
Norway 2018). 
3.2 Study populations 
This project is a population-based study. All women living in Norway and giving live 
births in the period January 1, 1999, to December 31, 2010, including their 
pregnancies (births), children, and fathers to their children, were defined as our study 
population. The study cohorts were identified through the Medical Birth Registry of 
Norway and constituted 429,004 women, 687,406 children, and 683,785 childbirths, 
including 434,686 fathers, with regard to the study of maternal cancer risk, childhood 
cancer risk, and paternal determinants of maternal periconceptional folic acid use, 
respectively (Table 1).  
The mothers take part in the study with several pregnancies during follow-up. To 
retrieve birth-related information, demographic data, maternal education and 
occupation, and cancer status, the study participants extracted from the Medical Birth 
Registry of Norway were linked to the National Registry, the Norwegian National 
Education Database, the Norwegian Labour and Welfare Administration, and the 
Cancer Registry of Norway, respectively, by using the national identification number 
(Table 1). For the researcher, the provided data files had the national identification 
numbers replaced with a project specific serial number. 
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We extracted information on children born alive during 1999 through 2010, including 
their registered mothers and fathers, from the Medical Birth Registry of Norway. The 
children were linked to the Cancer Registry of Norway, and their registered parents 
were linked to the National Registry, the Norwegian National Education Database 
and the Norwegian Labour and Welfare Administration by using the unique personal 
identification number. Since the parents can take part in the study with subsequent 
births, educational and occupational data at time of childbirth birth were used (Table 
1). 
 
Table 1: Inclusion criteria for publications 1 through 3 
      Publication  
Inclusion criteria Description 1 2 3 
Time period Year of childbirth 1999–2010 1999–2010 1999–2010 
MBRN notification  Information collected at childbirth Yes Yes Yes 
CRN notification Information collected at diagnosis Yes Yes  
NUDB Information collected at childbirth Yes Yes Yes 
NAV Information collected at childbirth1 Yes Yes Yes 
Unit of analysis  Mothers Children Births 
Initial study sample Number of subjects before exclusions 442,858 707,495 707,495 
Final study sample Number of subjects included in the analyses 429,004 687,406 683,785 
MBRN: Medical Birth Register of Norway. CRN: Cancer Registry of Norway. NUDB: The Norwegian 
National Education Database. NAV: The Norwegian Labour and Welfare Administration. 
 
In publication I, we included 429,004 women with births during 1999 through 2010 
registered in the Medical Birth Registry of Norway. Since information on 
supplemental use has not been registered for induced abortions, 2,491 individual 
records were excluded. Births to women who emigrated before birth (13,733) or who 
were diagnosed with cancer before delivery (3,334) were also excluded. We followed 
each woman from the date of her first childbirth during 1999–2010 until a cancer 
diagnosis (International Classification of Diseases version 10 [ICD-10]), death, 
emigration, or end of follow-up at December 31, 2010. 
                                              
1 Occupational codes registered in 2003 were applied for births during 1999–2002 
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The cohort for publication II consisted of all live-born children from January 1, 1999 
through December 31, 2010, constituting 687,406 children. We excluded 3,371 
children with mothers diagnosed with cancer prior to childbirth. The remaining 
children were followed from date of birth until diagnosis of their first cancer, 
emigration, death or end of follow-up at December 31, 2010. 
Our study population in publication III consisted of 683,785 births in Norway from 
January 1, 1999, through December 31, 2010 (434,154 mothers and 434,686 
registered fathers). Because information on folic acid use and paternal identification 
has not been registered for induced abortions, 2,519 records of births were excluded. 
Births without a paternal identification number (12,699) or maternal identification 
number (4,091) were also excluded.  
3.3 Exposure 
In Norway, folic acid supplements intended for use in pregnancy during 1999–2010 
contained 0.4 mg of folic acid, while most multivitamin supplements sold over the 
counter in all pharmacies contained approximately 0.2 mg of folic acid (Norwegian 
Scientific Committee for Food Safety 2015). The revised Medical Birth Registry of 
Norway notification form records information on folic acid and multivitamin 
supplementation by using checkboxes with the items “no” (no regular dietary 
supplementation), “folic acid before pregnancy,” “folic acid during pregnancy,” 
“multivitamins before pregnancy,” and “multivitamins during pregnancy.” Based on 
the guidelines for electronic notification of births to the Medical Birth Registry of 
Norway, and the user guide for electronic notification of births (Norwegian Institute 
of Public Health 2016), the check box referring to no supplementation has to be 
marked if the check boxes for “folic acid before pregnancy”, “folic acid during 
pregnancy”, “multivitamins before pregnancy”, and “multivitamins during 
pregnancy” are left unmarked. On the other hand, if the check box referring to no 
supplementation is unmarked, at least one of these other check boxes has to be 
marked in order to complete the form. 
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In publication I, we defined mothers as “folic acid users” if they used folic acid 
supplements before and/or during pregnancy. Based on this information for each 
mother in the cohort, we created an exposure variable for maternal folic acid use in 
successive pregnancies (no use, use in one pregnancy, and use in two or more 
pregnancies). Similarly, we defined the same mothers as “multivitamin users” if 
multivitamins were used before and/or during pregnancy. A multivitamin exposure 
variable for maternal multivitamin use in successive pregnancies was then 
constructed (no use, use in one pregnancy, and use in two or more pregnancies). 
Finally, we created a third exposure variable based on the total amount of folic acid 
from folic acid supplements (0.4 mg) and multivitamin supplements (approximately 
0.2 mg) before and/or during pregnancy. 
In publication II, children were regarded as exposed to folic acid in utero if their 
mothers used folic acid and/or multivitamin supplements before and/or during 
pregnancy. We categorized the “quantity” of folic acid intake by increasing amounts 
of folic acid content: no supplement use (0 mg), only multivitamins (approximately 
0.2 mg), only folic acid supplements (0.4 mg), or intake of both folic acid 
supplements and multivitamins (approximately 0.6 mg).  
In publication III, the following paternal determinants were used in the analyses of 
adequate maternal folic acid supplementation: paternal age (<20, 20–24, 25–29, 30–
34, 35–39, 40+ years); education (compulsory [1–9 years], intermediate [10–12 
years], and tertiary [13–19 years]); occupation according to the class scheme of 
Erikson, Goldthorpe and Portocarero (I Higher professionals, II Lower professionals, 
IIIa Higher routine, IIIb Lower routine, IV Other self-employed workers, V 
Technicians, VI Skilled, VII Semiskilled and unskilled, VIIb Agricultural, 
Unclassified) (Erikson and Goldthorpe 1992); and country of origin according to the 
classification by the World Health Organization’s Health Statistics and Information 
Systems’ estimates for 2000–2012 (Norway, high income countries, and low/middle-
income countries) (World Health Organization 2016). Paternal occupation was 
categorized according to Erikson, Goldthorpe and Portocarero class scheme by means 
of a manual provided by Flemmen et al. (Flemmen and Andersen 2009).  
 37 
3.4 Outcomes 
In publication I, we used the International Classification of Diseases version 10 
(ICD-10) to identify incident maternal cancer cases through linkage with the Cancer 
Registry of Norway (Table 2). Only the first cancer diagnosis was used in our 
analyses. Subgroups of maternal cancer included the 13 most frequent cancer 
subgroups in our cohort: colorectal cancer (C18–21), lung cancer (C33–34), 
melanoma of the skin (C43), non-melanoma skin cancer (C44), breast cancer (C50), 
cancer of the uterine cervix (C53), ovarian cancer (C56), central nervous system 
tumors (C70–72, D42–43), thyroid cancer (C73), cancer of the other endocrine glands 
(C37, C74–75), Hodgkin’s lymphoma (C81), non-Hodgkin’s lymphoma (C82–85, 
C96), and leukemia (C91–95, D45–47). 
Cancer types with less than 50 cases were categorized as “Other cancers” (C00–17, 
C22–26, C30–32, C38–41, C45, C47–49, C51–52, C54, C57–58, C64–69, C76, C80, 
C88, C90).  
In publication II, we identified the incident childhood cancer cases through linkage 
with the Cancer Registry of Norway. The first cancer diagnosis for each child was 
used and categorized according to the International Classification of Childhood 
Cancer, version 3, which is based on the ICD-O-3 (Steliarova-Foucher et al. 2005) 
(Table 2). 
In publication III, adequate maternal folic acid supplement use (folic acid use before 
and during pregnancy) was the outcome of investigation (Table 2). 
3.5 Covariates 
Covariates were extracted from the Medical Birth Registry of Norway, the National 
Registry, the Norwegian National Education Database, and the Norwegian Labour 
and Welfare Administration. The inclusion of covariates and potential confounders 
used in the statistical models are described below.  
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In publication I, we chose relevant covariates associated with maternal folic acid use 
and maternal cancer a priori, based on information in previous literature. Maternal 
year of birth (1949–59, 1960–69, 1970–79, 1980–89, 1990–96), maternal age at first 
childbirth in the study period (1999–2010) (<20, 20–24, 25–29, 30–34, 35–39, ≥40 
years), maternal age at first childbirth (prior to start of follow-up period) (<20, 20–24, 
25–29, 30–34, 35–39, ≥40 years), parity (1, 2, 3, ≥4), marital status (unmarried, 
married/registered partner/cohabitant, divorced/widowed), and smoking habits were 
collected from the Medical Birth Registry of Norway. Information on maternal 
smoking was recorded at the start and end of pregnancy (no smoking, sometimes, 
daily, the number of cigarettes, declined to inform about smoking habits). The 
smoking data was then categorized into a single variable that contained the maximum 
cigarette consumption for each woman: never, sometimes, ≤10 cigarettes daily, >10 
cigarettes daily, daily smoking–unknown amount. Data on length of maternal 
education (compulsory [1st–7th class level], intermediate [8th–12th class level], 
tertiary [13th–20th class level]) and maternal occupation at the time of first childbirth 
(1999–2010) was collected from the Norwegian National Education Database and the 
Norwegian Labour and Welfare Administration, respectively. Maternal occupation 
was categorized according to the International Standard Classification of 
Occupations, which is divided in 10 major groups: 0. Armed forces and unspecified , 
1. Legislators, senior officials and managers, 2. Professionals, 3. Technicians and 
associate professionals, 4. Clerks, 5. Service workers and shop and market sales 
workers, 6 Skilled agricultural and fishery workers, 7. Craft and related trades 
workers, 8. Plant and machine operators and assemblers, 9. Elementary occupations 
(Table 2). 
In publication II, we selected covariates associated with maternal folic acid 
supplementation and childhood cancer risk a priori (Table 2). These variables were 
collected from the Medical Birth Registry of Norway: number of births (1, 2, ≥3), 
maternal and paternal age (<25, 25–34, ≥35 years), and maternal smoking (never, 
sometimes, ≤10 cigarettes daily, >10 cigarettes daily, daily smoking of unknown 
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amount). From the Norwegian National Education Database we retrieved maternal 
and paternal education data (compulsory, intermediate, tertiary). 
In publication III, we used subject-matter knowledge and a directed acyclic graph 
(DAG) approach (Appendix 2) to assess the minimally sufficient adjustment set of 
variables when studying the association between potential paternal determinants and 
adequate maternal folic acid supplementation (Shrier and Platt 2008). We constructed 
a DAG that identified the unconfounded association of paternal determinants with 
adequate maternal folic acid supplementation (Pearl 2010, Shrier and Platt 2008, 
Textor et al. 2011). The final adjustment set blocked “non-causal” but not “causal 
pathways” between paternal determinants and maternal folic acid use, and included 
year of childbirth (1999– 010), father’s age (<20, 20‒24, 25‒29, 30‒34, 35‒39, 40+ 
years), education (compulsory, intermediate, tertiary), and country of origin (Norway, 
high-income countries, low/middle-income countries) (retrieved from the National 
Registry) (Appendix 2). 
Paternal age, education, and country of origin are related to maternal age, education 
and country of origin through the custom of marrying with those of the same age and 
sociological, educational, religious, and ethnic backgrounds (age and educational 
homogamy, and ethnic endogamy) (Çelikaksoy et al. 2009, Huber and Fieder 2011, 
van de Putte et al. 2009). Maternal age, education, and country of origin are 
associated with maternal folic acid use (Nilsen et al. 2006, Timmermans et al. 2008). 
We therefore included maternal age (<20, 20‒24, 25‒29, 30‒34, 35‒39, 40+ years), 
maternal education (compulsory, intermediate, tertiary), and maternal country of 
origin (Norway, high-income countries, low/middle-income countries) as potential 
confounders of the associations between paternal age, education, and country of 
origin, respectively, and adequate maternal folic acid use in a separate model. 
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3.6 Statistical analysis 
All statistical analyses were performed using STATA versions 13 and 14 (StataCorp. 
2013, StataCorp. 2015). For publications I and II, the statistical package SPSS 
version 22 was also used. 
Data were described as frequencies and risk estimates with confidence intervals (CIs). 
Potential confounding factors were chosen a priori as described above. For 
publication III, directed acyclic graphs were also used to minimize potential bias 
from intermediate variables when studying the association between potential paternal 
determinants and adequate maternal folic acid supplementation. Inclusions of 
confounders in the statistical models are discussed in more detail below, and 
information about the variables used is presented in Table 2. 
3.6.1 Folic acid and maternal cancer risk (publication I) 
In our study, the risk of total cancer and subtypes of cancer among women using folic 
acid in successive pregnancies compared to women using no folic acid were 
estimated as hazard ratios (HRs) with 95% confidence intervals (CIs) using 
multivariate, time-dependent Cox proportional hazard regression models (Cox and 
Oakes 1984). Time since the first childbirth from 1999 through 2010 was used as the 
time variable. The Cox models were applied when there was an underlying 
assumption of proportionality. Tests for linear trends over the categories of folic acid 
supplementation were calculated. All analyses were adjusted for maternal age at first 
childbirth (age at cohort entry), maternal year of birth, marital status, birth order, 
education, occupation, and smoking at time of birth. For total cancer and breast 
cancer only, we also adjusted for age at the woman’s first childbirth. 
In this publication, we also used multiple imputations on missing smoking status at 
the time of birth due to 16% of the births missing data on smoking. The imputed 
analyses were performed following the recommendation by White and Royston 
(White and Royston 2009). 
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3.6.2 Folic acid and childhood cancer risk (publication II) 
Cancer risk in children exposed to maternal folic acid and/or multivitamin 
supplements was compared with cancer risk in unexposed children and expressed as 
HRs with 95% CIs, using Cox proportional hazards regression models when there 
was an underlying assumption of proportionality. Time since birth was used as the 
time variable, and all analyses were adjusted for a priori selected covariates 
associated with maternal folic acid use and childhood cancer risk; that is, birth order, 
maternal smoking, maternal and paternal age, and maternal and paternal education. 
Maternal periconceptional folic acid and/or multivitamin use was divided into 
four exposure levels: 0 mg, approximately 0.2 mg, 0.4 mg and approximately 0.6 mg. 
A test for linear trends was calculated by treating the four exposure levels 
as continuous in the models (Table 2).  
3.6.3 Paternal characteristics associated with maternal 
periconceptional folic acid supplementation (publication III) 
To determine the associations between paternal determinants (age, education, 
occupation, country of origin) and maternal folic acid supplement use, crude and 
adjusted relative risks (RRs) with corresponding 95% CIs were calculated by log 
binomial regression models with the log-link function in STATA version 14 
(StataCorp. 2015). RR is the ratio of the risk of adequate maternal folic acid use for 
different categories of paternal determinants and the risk of adequate maternal folic 
acid use for the reference category of paternal determinants. Our analyses included 
robust variance estimation of the 95% CIs with the sandwich estimator, to correct for 
the intra-individual correlation in women with more than one pregnancy during the 
study period (Cameron and Miller 2015). All analyses were adjusted according to the 
description in Table 2. P-values for overall difference between the categories of 
paternal determinants were calculated using likelihood ratio tests. Effect modification 
of the association between paternal education and adequate maternal folic acid 
supplementation by maternal education was evaluated by stratification, and tested 
with likelihood ratio tests. 
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Table 2: Overview of the outcomes, exposure variables, adjustment 
variables, design, statistical models and statistical software used in this 
study 
Publication I Publication II Publication III 
Main outcome 
Maternal cancer (ICD-10)1 
Total cancer 
Colorectal cancer (C18–21) 
Lung cancer (C33–34) 
Melanoma of the skin (C43) 
Non-melanoma skin cancer (C44) 
Breast cancer (C50) 
Cancer of the uterine cervix (C53) 
Ovarian cancer (C56) 
Central nervous system tumors 
(C70–72, D42–43) 
Thyroid cancer (C73) 
Other endocrine glands2 (C37, 
C74–75) 
Hodgkin’s lymphoma (C81) 
Non-Hodgkin’s lymphoma (C82–
85, C96) 
Leukemia (C91–95, D45–47) 
“Other cancers” (C00–17, C22–
26, C30–32, C38–41, C45, C47–
49, C51–52, C54, C57–58, C64–
69, C76, C80, C88, C90) 





II. Lymphomas and 
reticuloendothelial 
neoplasms 
III. Central nervous system 
tumors and miscellaneous 
intracranial and 
intraspinal neoplasms 
IV. Neuroblastoma and other 
peripheral nervous cell 
tumors 
VI. Renal tumors 
IX. Soft-tissue and other 
extraosseous sarcomas 
   “Other cancers” 
Maternal folic acid use 
Adequate folic acid use 





Folic acid (before and/or during 
pregnancy) 
No use 
Use in one pregnancy 
Use in two or more pregnancies 
 
Multivitamins (before and/or 
during pregnancy) 
No use 
Use in one pregnancy 
Use in two or more pregnancies 
 
Total amount of folic acid from 
multivitamin and folic acid 
supplements (before and/or during 
pregnancy)4 
   0 mg 
~ 0.2 mg 
   0.4 mg 
~ 0.6 mg 
 
Total amount of folic acid from 
multivitamin supplements and folic 
acid supplements (before and/or 
during pregnancy) 
No use (0 mg) 
Multivitamins only (~ 0.2 mg)  
Folic acid only (0.4 mg) 
 Folic acid and multivitamins  















I Higher professionals 
II Lower professionals 
IIIa Higher routine 
IIIb Lower routine 















Adjustments (1999–2010)  
Maternal age (1999–2010) 
 <20 






Maternal age at the very first 
childbirth (for total and breast 
cancer only) 
 <20 



















Maternal marital status 
Unmarried 










Armed forces or unspecified 
Legislators, senior officials, and  
managers 
Professionals 
Technicians and associate  
professionals 
 Clerks 
Service workers and shop and 





























≤10 cigarettes daily 
>10 cigarettes daily 
Daily smoking, unknown amount 
For paternal age 
Year of childbirth 








For paternal education 

















For paternal occupation5 
Year of childbirth 
Paternal age 
< 20 
20 – 24  
25 – 29 
30 – 34 











For paternal country of origin 
Year of childbirth 





Agricultural, forestry, and fishery  
workers 
Craft and related trades workers 







≤10 cigarettes daily 
>10 cigarettes daily 





Population-based cohort study Population-based cohort study  Population-based cross-sectional 
study 
Statistical models 
Time-dependent Cox proportional 
hazard regression models 





SPSS version 22 and STATA 
version 13 
SPSS version 22 and STATA 
version 13 
 
STATA version 14 
1 International Classification of Diseases, 10th version 
2 Malignant neoplasm of thymus, adrenal gland, and other endocrine glands and related structures excluding 
endocrine pancreas, ovary, and thyroid. 
3  International Classification of Childhood Cancer, third edition (Steliarova-Foucher et al. 2005) 
4  We have used approximately (~) because multivitamins used in Norway during 1999–2010 initially 
contained 0 mg of folic acid and later contained 0.2 mg of folic acid. Folic acid supplements contained 0.4 
mg of folic acid throughout the study period (Norwegian Scientific Committee for Food Safety 2015). 
5  According to the class scheme of Erikson, Goldthorpe and Portocarero (EGP) (Erikson and Goldthorpe 1992) 
6  According to the classification of the World Health Organization’s Health Statistics and Information 
Systems’ estimates for 2000–2012, available from 
(http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html) 
7 Standard Classification of Occupation (STYRK-08 2011) (10 major groups) 
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3.7 Ethical approval 
The study was approved by the Regional Committee for Medical and Health 
Research Ethics of Western Norway (REK ref. number 2010/3310). 
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4. Results 
4.1 Maternal cancer risk (publication I) 
Our study population included 429,004 women, constituting 2,933,587 person-years. 
The mean age at the start of follow-up was 29 years (range 13–54 years). A total of 
3,781 cancer cases were diagnosed during follow-up, and the mean age at cancer 
diagnosis was 37 years (range 18–56 years). Figure 3 presents the number of cancer 
cases by maternal age at diagnosis during follow-up (1999–2010).  
 




Table 3: Cancer cases registered during follow-up according to cancer 
types and ICD-10 codes among 429,004 women in Norway, 1999–2010  
Cancer types ICD-10 codes Cancer cases (N) 




Colorectal C18–21 169 
Lung & trachea C33–34 54 
Melanoma of the skin C43 494 
Skin, non-melanoma C44 51 
Breast C50 1,166 
Cervix uteri C53 457 
Ovary C56 74 
Central nervous system C70–72, D42–43 357 
Thyroid C73 252 
Other endocrine glands C37, C74–75 91 
Hodgkin’s lymphoma C81 84 
Non-Hodgkin’s lymphoma C82–85, C96 93 
Leukemia C91–95, D45–47 96 
Other cancers C00–17, C22–26, C30–32, C38–41, C45, 343  
C47–49, C51–52,  C54, C57–58, C64–69 
 
 
C76, C80, C88, C90 
 
 
Mean time between the first birth in the study period and cancer diagnosis was five 
years (range 0.1–12 years). The most frequent cancer type in the cohort was breast 
cancer (1,166 cases), followed by melanoma of the skin (494) and cancer of the 
uterine cervix (457) (Table 3). 
Analyses showed no increased overall risk of cancer among women using folic acid 
in one (HR 1.08; 95% CI 1.00–1.18) or two or more pregnancies (HR 1.06; 95% CI 
0.91–1.22) compared to no folic acid use (ptrend=0.12). However, subgroup analyses 
indicated an increased risk of borderline significance for lung cancer (ptrend=0.06) and 
thyroid cancer (ptrend=0.05) in relation to folic acid use compared to no use. Analyses 
of folic acid use in relation to other cancer types showed no effect on the risk 
estimates compared to no use. 
We conducted similar analyses for multivitamin supplementation that showed no 
increased overall risk of cancer. However, increased risk was found for melanoma of 
the skin among women using multivitamins in one (HR 1.19; 95% CI: 0.96‒1.48) and 
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two or more pregnancies (HR 1.58; 95% CI: 1.05‒2.38) compared to no use 
(ptrend=0.02). Additionally, increased risk of non-Hodgkin’s lymphoma was seen 
among multivitamin users in one (HR 1.54; 95% CI: 0.94‒2.53) and two or more 
pregnancies (HR 2.82; 95% CI: 1.15‒6.95) compared to no use (ptrend=0.01).   
4.2 Childhood cancer risk (publication II) 
The study included 687,406 children (born during 1999–2010), and among them, 799 
were diagnosed with cancer. In general, childhood cancer occurred more frequently 
among males (423) than females (376). The average follow-up time was 6 years 
(range 0.04–12 years), constituting 4,052,679 person-years. Maternal age at childbirth 
was in the age range of 13 to 55 years.  
The proportion of children exposed to perigestational folic acid supplementation 
increased in the study period from 18% to 69% and multivitamin supplementation 
increased from 19% to 42%. About 67% of childhood cancer cases were diagnosed 
within the first 3 years of age (Table 4). Leukemia and central nervous system tumors 
accounted for 57% of the cancer cases.  
No change was found in overall childhood cancer risk for maternal use of 
multivitamins only (HR 1.05; 95% CI 0.78–1.42), folic acid use only (HR 1.13; 95% 
CI 0.92–1.38), and combined folic acid and multivitamin use (HR 1.02; 95% CI 
0.83–1.25) as compared to no maternal supplement use (ptrend 0.60). There was no 
difference in risk estimates between males and females. Likewise, subgroup analyses 
of the six most frequent childhood cancer types (leukemia, lymphoma, central 
nervous system tumors, neuroblastoma, Wilms’ tumor, and soft-tissue tumors) 
showed no change in risk. 
4.3 Paternal characteristics associated with maternal 
periconceptional folic acid supplementation (publication III) 
Use of adequate folic acid supplements during 1999–2010 is presented in Figure 4. 
Adjusted analyses showed that the association between paternal age and adequate 
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maternal folic acid use was inversely U-shaped; adjusted RRs for adequate use were 
0.35 (95% CI 0.28–0.43) and 0.72 (95% CI 0.71–0.74) for paternal age <20 and ≥40 
years, respectively, comparing age 30–34 years. Compulsory education (1–9 years) 
among fathers was compared to tertiary education (14–20 years); the RR was 0.69 
(95% CI 0.68–0.71) for adequate use. Occupation classes other than “Higher 
professionals” were associated with decreased risk of adequate folic acid use, 
compared with the reference “Lower professionals.” Finally, the RR for adequate use 
was 0.58 (95% CI 0.56–0.60) comparing fathers born in “Low/middle-income 
countries” with fathers born in Norway. 
Stratified analyses of recommended periconceptional folic acid supplementation by 
maternal and paternal education showed that adequate folic acid use was less likely in 
births where fathers had compulsory education, regardless of maternal education. The 
association of paternal compulsory education and recommended folic acid use was 
weakened by increasing levels of maternal education. However, even when the 
mother had reached tertiary education, the association of compulsory paternal 
education with recommended maternal folic acid use was significant (RR 0.75; 95% 









5.1 Methodological considerations 
5.1.1 Study designs 
The studies on the association between maternal folic acid supplementation in 
pregnancy and maternal and childhood cancer risk have a population-based cohort 
design. The study of paternal characteristics of maternal folic acid supplementation 
has a cross-sectional design. The study populations used in our research were based 
on a linkage of population-based registries in Norway with comprehensive 
information for each individual, which makes it possible to produce association 
measures with high precision and assures generalizability of our results. Furthermore, 
the Norwegian population is relatively stable and emigration rates are low, and the 
national registries record statuses of immigration, emigration or deaths continuously 
for residents of Norway (Statistics Norway 2017).  
5.1.2 Internal validity 
Internal validity indicates the strength of inference based on the findings for the study 
population (Rothman et al. 2008i). In other words, it determines the extent to which 
the association observed in a study is due to independent variables and no other 
factors. The internal validity is good if the calculated estimate is minimized for 
systematic errors or biases. The presence of systematic errors that include selection 
bias, information bias, and confounding may reduce the internal validity of the study  
(Rothman et al. 2008i). 
Selection bias 
Selection bias is a distortion that occurs when the selection of subjects for a study, or 
the likelihood of them being retained in the study, leads to a result that differs from 
what would happen if the entire target population was enrolled (Rothman et al. 
2008h). Common causes of selection bias in a cohort study are missing data, 
exclusion of study subjects, or short follow-up. 
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In publications I and II, information on maternal smoking was missing for 16% of the 
births. We performed analyses with and without maternal smoking as a covariate in 
the models. We found the HR estimates of maternal cancer and childhood cancer 
were similar when analyzing with and without the covariate maternal smoking. 
Furthermore, multiple imputation analyses (publication I) on missing smoking status 
at time of birth showed no substantial changes in the HR estimates. Further, in 
publication III, we lacked information on the father for about 2% of the births. These 
represented births with fathers unreported by the pregnant woman or fathers without 
an identification number assigned by the National Registry. Since the percentage of 
missing fathers was less than 10%, there was no reason to perform multiple 
imputation analyses, and removal of the missing cases was a reasonable solution 
(Cismondi et al. 2013). As information was missing for 4.4% of the births on paternal 
education and 7.7% of the births on paternal occupation, it was also reasonable to 
remove these missing cases from the analyses. 
Our study is based on population-based register data that are compulsory, and loss to 
follow-up or selective reporting is minimal. The three study populations included the 
entire population of women giving birth in Norway during 1999–2010, live children 
born between 1999 and 2010, and all registered births in Norway from 1999 through 
2010. This is unlikely to cause serious selection bias, and it is thus assumed to have 
no influence on the results of our research.  
Our analyses may be affected by short follow-up, which causes selection bias where 
the time-period of cohort follow-up is too short for an outcome to appear 
(Encyclopedia of Epidemiology 2008). A challenge regarding publications I and II is 
the relatively short follow-up time of our study population. In publication I, the 
follow-up time was, on average, 7 years. The mean time between the first birth in the 
study period and cancer diagnosis was 5 years. Further, the average follow-up time in 
publication II was 6 years, and the mean time from birth to childhood cancer 
diagnosis was 3 years. Cancer is a heterogenic disease and may develop over decades. 
Thus, it is important that an observational study has appropriate follow-up to identify 
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cancer cases. A longer follow-up would probably detect more cancer cases and 
increase the strength of our analyses. 
Information bias 
Information bias is an error that results from incorrect classification or measurement 
of the exposure or outcome of interest (Rothman et al. 2008d). Classification errors of 
exposure or outcome that depend on the values of other variables are defined as 
differential misclassification. Classification errors of exposure or outcome that do not 
depend on the values of other variables are defined as non-differential 
misclassification.  
Differential misclassification is systematic errors initiated by differences in the 
exactness or completeness of memory recollections reported by study participants 
concerning an event (recall bias) or systematic errors initiated because of selective 
revealing or suppression of information by individuals (reporting bias) (Rothman et 
al. 2008b). Such errors exist if an individual who has the outcome of interest has 
better recall of the exposing factor than those who do not have the outcome of 
interest. Selective revealing or suppression of information by individuals in the 
present study is not likely because our data were collected from compulsory 
population-based registries, though independent of each other. Concerning 
publications I, II and III, details of all folic acid exposures were collected 
retrospectively during hospitalization at the time of birth. Although this registration 
may be susceptible to recall bias, it is unlikely that vitamin supplements have been 
recalled differently among the mothers. Relating to publications I and II, information 
on supplement use was recorded before a cancer diagnosis, thus precluding recall 
bias. Most childbearing women know the adverse health effects of smoking, and they 
may be subject to social or medical disapproval. Self-reported smoking status may 
reduce the reliance of smoking data in our study. However, the smoking habits were 
documented before a possible cancer diagnosis. Furthermore, a validation study of 
self-reported smoking in Norway confirms the high validity of self-reported smoking 
in population-based studies (Kvalvik et al. 2012). 
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Non-differential misclassification means that the frequency of errors is equally 
distributed in the groups being compared. Non-differential misclassification of 
exposure may occur when records are incomplete due to incorrect registration, 
incorrect coding of disease diagnosis or errors in interpreting information from 
records. This leads to an underestimate of the risk and an incorrect conclusion 
(Sorahan and Gilthorpe 1994). When the exposure variables are dichotomous, non-
differential misclassification tends to produce analysis estimates toward the null value 
(Rothman et al. 2008f). In other words, if there is an association, non-differential 
misclassification will minimize the association.  
Registration of births in the Medical Birth Registry of Norway is performed by health 
personnel in attendance during hospitalization. Folic acid and multivitamin 
supplementation may have been registered incorrectly or underreported by the 
hospitals. Moreover, the health personnel in attendance may have provided incorrect 
information or failed to obtain information from the mothers. A possible 
misclassification of folic acid supplementation (independent of cancer risk) would 
bias risk estimates toward the null value and, in theory, may conceal an association 
between folic acid intake and maternal or childhood cancer risk. 
Folic acid supplement use registered in the Medical Birth Registry of Norway has 
previously been validated against data from the Norwegian Mother and Child Cohort 
Study (MoBa) (Nilsen et al. 2009). Participants in the MoBa study (N = 73,579) were 
compared with women registered with births in the Medical Birth Registry of Norway 
(N = 398,849) during 2000–2006. The prevalence of folic acid use was substantially 
higher among MoBa participants. However, examination of differences in association 
measures for eight exposure-outcome associations showed no statistical relative 
difference for folic acid supplementation between women registered in the Medical 
Birth Registry of Norway and participants of the MoBa study. This finding 
demonstrates according to Nilsen et al. no bias in exposure–outcome associations, 
and the authors consider the Medical Birth Registry of Norway as a reliable data 
source of maternal supplement use when studying measures of association, but not 
for prevalence studies.  
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Registration of malignant tumors is compulsory in Norway, and the Cancer Registry 
of Norway registers all incident cancers in Norway. Health professionals and 
pathology laboratories involved in the diagnosis, treatment, and monitoring of cancer 
patients must report to the registry. Although the validity of the cancer registration is 
good, underreporting or misclassification of a cancer diagnosis may occur. Estimation 
by the capture/recapture method showed that the overall completeness of the Cancer 
Registry of Norway data during 2001–2005 was 98.8%, and the overall completeness 
5 years after time of diagnosis was 97.8% (Larsen et al. 2009). The difference in 
completeness between the Cancer Registry of Norway data during 2001–2005 and the 
overall completeness 5 years after the time of diagnosis may represent under-
reporting of malignancies or delayed notifications of cancer cases. 
Confounding  
Confounding implies that a “third” variable adversely affects the relation between the 
exposure of interest and the outcome (Rothman et al. 2008a). When confounding is 
present, the confounding variable has to be associated with the exposure in the source 
population, as well as being a risk factor of the outcome. This variable must not be an 
intermediate step in the causal pathway (Rothman et al. 2008a). In epidemiologic 
research, adjustments may increase bias through overadjustment or unnecessary 
adjustment (Schisterman et al. 2009). Unnecessary adjustment may be defined as 
control for a variable that does not affect the causal relation between exposure and 
outcome, but can affect its precision. Contrary to unnecessary adjustment, lack of 
important data may lead to unknown or unmeasured confounding (residual 
confounding) (Rothman et al. 2008e). Since confounding is a distortion that causes an 
outcome to be falsely attributed to another variable, it is important to address it in 
order to make valid causal inferences from observational data. Directed acyclic 
graphs (DAGs) give a visual representation of causal assumptions and help to identify 
the presence of confounding for a causal model (Pearl 2010, Shrier and Platt 2008, 
Textor et al. 2011). 
In publications I and II, the potential confounding variables were chosen a priori and 
examined according to their influence on the risk estimates. In publication III, 
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subject-matter knowledge and DAGs (Appendix 2) were used to identify the 
unconfounded association of paternal determinants with adequate maternal folic acid 
supplementation (Pearl 2010, Shrier and Platt 2008, Textor et al. 2011). 
In publication I, the models were adjusted for maternal age at first childbirth (age at 
cohort entry) during 1999–2010, maternal year of birth, parity, marital status, 
education, occupation, and smoking status at the time of birth. Age in our study 
relates to cancer because cancer incidence increases with age (White et al. 2014). 
Women who have their first full-term pregnancy at a young age have a lower risk of 
developing hormone receptor positive breast cancer later in life than women who 
have their first child later in life (at 30 years or more) (Bernstein 2002). Since breast 
cancer was the most frequent cancer type in our cohort, we therefore adjusted risks 
for breast cancer and total cancer for maternal age at first childbirth (including first 
birth before cohort entry in 1999).  
We had no information on maternal weight and height, physical activity, diet or use 
of alcohol. High BMI, low physical activity and high alcohol use are associated with 
the risk of some cancer types (Bagnardi et al. 2001, Bhaskaran et al. 2014, I. M. Lee 
et al. 2012). Alcohol use, known to antagonize folate absorption and metabolism, is 
unlikely to be an important confounder as the consumption of alcohol during 
pregnancy is generally low in Norway. In our study, we could not control for health-
related covariates other than smoking. Therefore, confounding from other risk factors 
is possible. However, adjustment for smoking and other existing covariates showed 
no change in the risk estimates, suggesting reduced likelihood of residual 
confounding.  
In publication II, the final models included birth order, maternal smoking, maternal 
and paternal age, and maternal and paternal education.  
We had no information on dietary folate. However, residual confounding by dietary 
folate is less likely. Maternal plasma levels of serum folate are strongly related to 
folic acid supplementation (Bjorke-Monsen et al. 2013), and two other studies of 
maternal periconceptional folic acid supplement use and offspring oral clefts and 
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autism risks have shown that adjustment for dietary folate did not change overall risk 
estimates (Suren et al. 2013, Wilcox et al. 2007).  
Information on the mother’s weight and height, physical activity, diet, use of alcohol, 
or use of contraceptive pills were not available in our data. Consequently, 
confounding from other risk factors may occur. Maternal height and weight before 
pregnancy are, however, available in the Medical Birth Registry of Norway from 
2007 and onwards, but are currently reported from only 40% of the birth clinics (T. 
Nilsen et al. 2016).  
In publication III, the models were adjusted for year of childbirth, father’s age, 
education, and country of origin. In addition, we included maternal age, education, 
and country of origin as possible confounders of the associations between paternal 
age, education, or country of origin, and maternal adequate folic acid use.  
We had no information on pregnancy planning, maternal physical activity or maternal 
use of alcohol. Since these covariates are related to maternal periconceptional folic 
acid use, confounding from other risk factors is possible. 
Maternal smoking was not considered a potential confounder of the association 
between paternal determinants and adequate maternal folic acid supplementation. A 
cross-sectional study showed that maternal smoking before pregnancy was not an 
independent determinant of preconception folic acid use (R. M. Nilsen et al. 2016).  
Effect modification 
Effect modification is distinct from confounding in that it occurs when an exposure 
has different effects among different subgroups, and it is only associated with the 
outcome but not the exposure (Greenland et al. 2008).  
We evaluated effect modification by stratification and by including an interaction 
term in the regression models.  
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The rationale for evaluating maternal education as an effect modifier was that 
maternal education seems to be positively associated with paternal education (van de 
Putte et al. 2009).  
In publication III, the relationship of compulsory paternal education and 
recommended maternal folic use was reduced by increasing level of maternal 
education. However, even when the mother had tertiary education, the relationship of 
compulsory education among fathers on recommended folic acid supplementation 
was significant, thus suggesting an interaction between them. 
5.1.3 External validity 
Generalizability or external validity refers to the extent to which the results and 
conclusions of a study can be generalized to the world at large (Rothman et al. 
2008c). Internal validity is a prerequisite for external validity because a study must 
demonstrate that the exposure is the cause of variation in the outcome before one can 
generalize that the exposure causes the outcome (Juul 2013). 
To achieve high external validity of our results, we need the study population to be 
representative of other, larger populations in other places and at other times. Since 
our study is a population-based study, external validity would apply to populations 
where welfare, education and healthcare are similar to Norway.  
In publication I, our finding of no association between folic acid supplementation and 
cancer risk is in accordance with several prospective cohort studies and meta-analyses 
(populations geographically and ethnically different from ours) showing no overall or 
site-specific relation between folic acid use and cancer risk (Hankey et al. 2012, Qin 
et al. 2013, Vollset et al. 2013, Zhang et al. 2008). In publication II, we found no 
relationship between periconceptional folic acid supplementation and major 
childhood cancers. This is in discordance with a large international collaborative 
study, including 47,000 children with acute leukemia and 11,000 controls, finding 
reduced risks of ALL and acute myeloid leukemia (AML) after maternal intake of 
folic acid supplements (Metayer et al. 2014). Moreover, our results in publication II 
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can only be generalized to younger children since our cohort was followed for an 
average of 6 years. 
5.1.4 Precision 
Precision in epidemiologic measurements refers to the extent or reduction of random 
errors (Rothman et al. 2008g). In general, we can improve precision by increasing the 
study size or modifying the study design.  
Our data is large and nationwide with balanced groups (i.e., folic acid exposure, no 
folic acid exposure, with cancer, without cancer) which produces more precise 
estimates (Rothman et al. 2008g). We used 95% confidence interval (i.e., 5% 
possibility that the observed association is the result of chance) and the width of these 
intervals reflects the precision.  
Despite our large study population, the sub-analyses had smaller numbers of events. 
In publication I, the association between folic acid supplementation prior to and 
during one or two or more pregnancies and the relatively low number of subtypes of 
maternal cancer cases, compared with a large sample size with no supplement use, 
yielded less precise estimates, as is indicated by the widths of the confidence 
intervals. Additional stratification of exposure into “use before pregnancy” and “use 
during pregnancy” was consequently not feasible. In publication II, the association 
measures between supplemental folic acid in pregnancy and childhood cancer, as 
compared to no supplement use, generated estimates of reduced precision due to a 
small number of children with cancer. Further stratification into preconceptionally 
use and use during pregnancy was also not reasonable in this publication. In 
publication III, the proportion of mothers using folic acid supplements and the 
distribution of fathers across paternal age, education, occupation, and country of 
origin may affect the precision of the study estimates. However, as shown by the 
relatively narrow confidence intervals, the association measures between paternal 
determinants and adequate maternal folic acid use yielded precise estimates. 
Nevertheless, a small number of individuals in some subgroups gave wider 
confidence intervals.  
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The categorization of our data may also affect precision. In publication I, we 
categorized the cancer cases according to ICD-10 into 13 main groups that were 
studied in detail. Among all maternal cancer cases, 1% had taken folic acid before, 
15% during, and 9% before and during pregnancy. Taking into account that the 
mothers were studied in one pregnancy or two or more pregnancies, the number of 
cancer cases decreased substantially for each following birth: 1,214 cancer cases 
among mothers with only one pregnancy, and 298 cancer cases among mothers with 
two or more pregnancies. Even among the most frequent cancer types, the number of 
folic acid users and cancer cases dropped substantially. 
In publication II, we divided the childhood cancer cases according to the ICCC-3 into 
six categories (leukemia, lymphoma, central nervous system tumors, neuroblastoma, 
Wilms’ tumor, and soft-tissue tumors). In order to account for the low number of 
childhood cancer cases and the number of children exposed to supplements, only the 
major childhood cancer groups were evaluated in the analyses.  
In conclusion, precision of the estimates in our study is generally not a problem when 
inferences are based on the overall results. 
5.2 Discussion of results 
Our nation-wide cohort study of all live births in Norway during 1999–2010, showed 
no association between maternal periconceptional folic acid supplementation and 
maternal cancer. Similarly, maternal folic acid supplementation in pregnancy was not 
associated with risk of major childhood cancers in offspring. 
Our population-based cross-sectional study showed that paternal characteristics; 
fathers who were younger and older at their infant’s birth, had achieved a lower level 
of education, had a manual or self-employed occupation, or originated from 
low/middle-income countries, were associated with inadequate maternal folic acid 
use in Norway from 1999 through 2010. 
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5.2.1 Maternal cancer risk (publication I) 
Our findings of no relation between maternal periconceptional folic acid 
supplementation and overall or site-specific cancer are in accordance with a meta-
analysis of 13 randomized controlled trials, comprising about 50,000 participants who 
were allocated to folic acid or to a placebo, and observed for 5 years. The authors 
reported no association between folic acid supplementation and cancer incidence 
(overall or subtypes of cancers) compared to the placebo (Vollset et al. 2013). 
Further, during 2000–2004, about 8,000 patients from 10 countries who had suffered 
a recent stroke or transient ischemic attack were randomly assigned to receive B 
vitamins (2 mg of folic acid, 25 mg of vitamin B6, and 0.5 mg vitamin B12) or a 
placebo. Consistent with our results, the study found no relation between participants 
allocated to B vitamins compared to the placebo and cancer incidence (Hankey et al. 
2012). Moreover, in compliance with our findings, a randomized controlled trial 
comprising approximately 5,000 female health workers aged 42 years or older with a 
preexisting cardiovascular disease or having coronary risk factors in the US during 
1998–2005, reported no association between combined folic acid, vitamin B6, and 
vitamin B12 treatment and overall cancer or breast cancer risk compared to the 
placebo (Zhang et al. 2008).   
In line with our results, a case-control study encompassing 2,491 women with breast 
cancer and 2,521 matched controls in Europe (Denmark, Italy except Naples, the 
Netherlands, Norway, Spain, Sweden and UK) reported no relationship between 
plasma concentration levels of folate and vitamin B12 and breast cancer risk (Matejcic 
et al. 2017). However, in contrast to our finding of no association between folic acid 
supplementation and breast cancer risk, a prospective cohort study including 25,400 
postmenopausal women in the US showed that high folate intake (>0.8 mg) was 
associated with increased risk of breast cancer compared to no use (Stolzenberg-
Solomon et al. 2006). The authors commented that their observed results might be 
due to chance or uncontrolled confounding.  
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In our study, use of folic acid supplements was not associated with lung cancer risk. 
This finding is concurrent to the observations from the Vitamin Lifestyle cohort study 
encompassing 77,118 participants in the age range of 50 to 76 years during 2000–
2002 in the US that reported no association between supplemental folate, vitamin B6 
or vitamin B12 and lung cancer risk among women (Brasky et al. 2017). However, the 
authors observed increased lung cancer risk among men using vitamin B6 and B12, but 
not among women. 
Contrary to our finding of no relationship between folic acid supplement use and 
colorectal cancer, a randomized controlled multi-center trial in China, comprising 791 
participants randomized to receive either 1 mg/day folic acid supplement or treated 
without folic acid and followed for 3 years, showed a decreased risk of colorectal 
cancer (Gao et al. 2013). However, similar to our results, a meta-analysis of nested 
prospective case-control studies on circulating folate and colorectal cancer (3,477 
cases and 7,039 controls) showed no association between circulating folate 
concentrations and colorectal cancer risk (Chuang et al. 2013). Moreover, the authors 
observed an inverse association between circulating folate and colorectal cancer risk 
in case-control studies that measured folate by radioimmunoassay compared to case-
control studies using microbiological assay. According to the authors, this finding 
could reflect differences in cohort and study design rather than assay performance 
(Chuang et al. 2013). Furthermore, prospective studies of natural food folates and 
folic acid intake suggest that high folate intake may reduce the risk of colorectal 
cancer (Kennedy et al. 2011, Lee et al. 2011, Stevens et al. 2011). As opposed to 
these findings, results from prospective studies on blood folate levels are inconsistent 
and cannot confirm a proposed protective role for colorectal cancer (Eussen et al. 
2010, J. E. Lee et al. 2012, Takata et al. 2014, van Guelpen et al. 2006, Weinstein et 
al. 2008). A population-based case-control study from Sweden, comprising 226 
colorectal cancer cases and 437 matched controls with median age about 60 years, 
showed a “bell-shaped” association between plasma folate concentrations and 
colorectal cancer risk (van Guelpen et al. 2006). The authors observed a doubling of 
colorectal cancer risk among individuals in the middle compared to lowest plasma 
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folate quintile. Another population-based, nested case-control study from Sweden, 
with 331 cases, 662 matched controls and followed for median 10.8 years, revealed 
that low plasma folate concentrations were related to low colorectal cancer risk in a 
population with low folate status (Gylling et al. 2014). The authors proposed that low 
folate status might have a protective role for colorectal cancer or suppress progression 
of preneoplastic or neoplastic lesions. A potential explanation for these discordant 
results might be that studies assessing folate exposure by dietary intake seem to 
encompass larger cohorts than studies using blood folate concentrations. 
Consequently, studies of blood folate concentrations could have less statistical power 
to detect a potential protective association between folate and colorectal cancer. On 
the other hand, blood folate concentration reflects the intake of natural folate through 
diet as well as ingested folic acid supplements. Further, folate intake is measured 
either as dietary folate from foods or as total folate from both dietary folate and folic 
acid supplements (Park et al. 2013). In some epidemiologic studies, it is not always 
clear whether intake from folic acid supplements has been included in the dietary 
assessments. On the other hand, the dietary sources of folate from fruits, vegetables 
and cereals contain other important vitamins, fibers and minerals that may have 
independent cancer-protective influence (Larsson et al. 2006, Song et al. 2015). 
Interestingly, Kim has proposed a potential dual modulatory role of folate on 
colorectal cancer based on animal studies (Kim 2007). In normal colorectal mucosa, 
folate deficiency appears to stimulate the initial stages of carcinogenesis, and 
supplementation of moderate doses of folic acid may suppress, whereas high doses of 
folic acid may enhance the development of cancer (Kim 2007). On the other hand, 
folic acid supplementation may enhance the growth of cancer cells in established 
neoplastic foci, whereas folate deficiency may inhibit progression of established 
colorectal neoplasms (Kim 2007). Similarly, Ulrich and Potter suggest that folate 
administration before the presence of preneoplastic lesions may prevent neoplastic 
development, whereas folate supplementation may increase tumor formation once 
early neoplastic lesions are established (Ulrich and Potter 2007). A potential dual role 
of serum folate in the development and progression of colorectal cancer in humans is 
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supported by findings in a case-control study by Chiang et al. and the nested case-
control study by Gylling et al. (Chiang et al. 2014, Gylling et al. 2014). 
We found no association between multivitamin supplementation and overall cancer 
risk. This is also supported by other studies reporting weak or no associations 
between multivitamin use and total cancer risk (Neuhouser et al. 2009, Park et al. 
2011). A cohort study comprising about 180,000 participants (aged 45–75 years) in 
Hawaii and California between 1993 and 1996 showed no association between 
multivitamin supplementation (information based on mailed questionnaire) and 
cancer risk, overall or for subtypes of cancer, compared to no use (Park et al. 2011). 
An observational study comprising about 160,000 postmenopausal women (aged 50–
79 years) in the US between 1993 and 1998 analyzed health and risk factors for 
cancer, and other illnesses, in relation to multivitamin use. Multivitamin use was 
collected at baseline and at follow-up time points during in-person clinic visits, and 
the women were followed for 8 years. The authors found no association between 
multivitamin use and cancer risk, compared to no use (Neuhouser et al. 2009). 
Similar to our findings of increased risk of malignant melanoma among women using 
multivitamins compared to no supplement use, the authors of a randomized, double-
blinded, placebo-controlled trial comprising 7,876 women (aged 35–60 years) and 
5,141 men (aged 45–60 years) in France suggested that antioxidant supplementation 
increases the incidence of skin cancers, including melanomas, in women but not in 
men (Hercberg et al. 2007). However, their findings have been criticized because of 
flaws in their study methods and in the interpretation of the results (Green et al. 
2008). Though, our finding of increased risk of malignant melanoma is in 
discordance with a previous prospective cohort study, comprising 69,671 men and 
women, on self-reported antioxidant supplement use and melanoma risk in the US, 
showing no increased melanoma risk (Asgari et al. 2009).  
Our finding of increased risk of non-Hodgkin’s lymphoma among women using 
multivitamin supplements compared to no supplement use is in concordance with a 
pooled cohort study (involving 88,410 women and 47,336 men in the US) on the use 
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of individual vitamin and multivitamin supplements and the risk of non-Hodgkin’s 
lymphoma (Zhang et al. 2001). This study showed that multivitamin use was related 
to a higher risk of non-Hodgkin’s lymphoma among women, but not among men, and 
the authors concluded that their observed findings were the results of chance. 
However, most non-Hodgkin’s lymphoma cases occur in individuals older than 60 
years (Zhang et al. 2011), which is considerable older than the mean age at cancer 
diagnosis in our cohort (37 years).  
Several possible mechanisms have been proposed by which folate or the bioactive 
form of folic acid may modulate cancer risk. Low folate status causes uracil 
incorporation in DNA and DNA strand breaks (Berger et al. 2008). The DNA breaks 
lead to fragmentation and rearrangement of the chromosomes that causes generation 
of cells with aberrant karyotypes and altered genes, which may promote cancer 
development (Duthie 2011). Further, a common single nucleotide polymorphism in 
the MTHFR gene (MTHFR 677C→T polymorphism) is connected to reduced 
MTHFR enzyme activity and function that is important for the methylation and 
nucleotide pathways (Figueiredo et al. 2013, Liew and Gupta 2015). Moreover, the 
MTHFR 677C→T polymorphism is related to colorectal cancer, uterine cervical 
cancer (Liew and Gupta 2015), and breast, esophageal, gastric and pancreatic cancers 
(Boccia et al. 2008, Ericson et al. 2009, Larsson et al. 2006). Further, a meta-analysis 
comprising 360 thyroid cancer cases and 900 controls reported that the MTHFR 677C 
→T polymorphism was associated with increased thyroid cancer risk (Yang et al. 
2014). We had no information on MTHFR polymorphisms in our study, but we 
observed an increased risk of borderline significance of thyroid cancer among women 
using folic acid supplements in one or two or more pregnancies compared to no 
supplement use. 
Our study of maternal cancer risk and folic acid supplementation was limited by a 
lack of records on frequency, or precise duration of folic acid and multivitamin use 
throughout pregnancy. Individual maternal data on MTHFR polymorphism status and 
blood folate level would have been beneficial to our study. An additional concern in 
our study is latency in cancer development. A longer follow-up period would have 
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increased the size of our study population, and more cancer cases may have been 
detected, which would have strengthened the statistical power of our analyses. 
Presently, there is no evidence to support a significant causal effect of folic acid on 
cancer because there are insufficient data available (Moussa et al. 2016, Scientific 
Advisory Committee on Nutrition 2017). In our study, we found no association 
between maternal periconceptional folic acid supplementation and cancer risk 
(overall and site-specific). However, we could not assess the long-term risk of folic 
acid use in pregnancy for maternal cancer.   
5.2.2 Childhood cancer risk (publication II) 
Our analyses of estimated maternal intake of folate from folic acid supplements, 
multivitamins, and combined use of these supplements showed no association with 
leukemia, lymphoma, childhood brain tumors, neuroblastoma, Wilms’ tumor, or soft-
tissue tumors (ICCC-3). In line with our finding of no relation between folic acid and 
leukemia, a case-control study from the US (357 cases and 405 matched controls 
from the Northern California Childhood Leukemia Study during 1995–2002) reported 
no association between birth folate concentrations and risk of childhood leukemia 
(Chokkalingam et al. 2013).  
However, our results are in discordance with previous case-control studies that 
showed an inverse association between self-reported folic acid supplementation and 
ALL or central nervous system tumors (Metayer et al. 2014, Milne et al. 2012, Milne 
et al. 2010, Thompson et al. 2001). A case-control study from Western Australia (83 
cases and 166 matched controls during 1984–1992) reported a strong inverse 
association between maternal folic acid supplementation during pregnancy and ALL 
(Thompson et al. 2001). However, this study was not designed to investigate the 
association between self-reported folic acid supplementation and ALL, and the 
findings were unexpected. Because of these findings, two studies followed: A 
prospective, national, population-based, multicenter case-control study (416 cases and 
1,361 matched controls during 2003–2007) on maternal use of folic acid and other 
vitamins before and during pregnancy, and a meta-analysis based on the results from 
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previous studies (Milne et al. 2010). The authors found some evidence of an inverse 
association between preconceptional folic acid use and ALL, including a weak, 
inverse dose-response relationship, but no association between folic acid 
supplementation use during pregnancy and ALL. A possible protective role of folic 
acid against ALL has been suggested in an international case-control study that 
included 7,000 children with ALL and 11,000 controls (during 1980–2012), which 
reported reduced risk of ALL and acute myeloid leukemia after maternal intake of 
folic acid supplements and other vitamins before or during pregnancy (Metayer et al. 
2014). Similarly, high intake of folic acid and other one-carbon metabolism nutrients 
from food and supplements combined was also associated with reduced ALL risk in a 
case-control study in the US comprising 681 ALL cases, 103 AML cases, and 1,076 
matched controls (Singer et al. 2016). 
An Australian case-control study of childhood brain tumors was performed between 
2005 and 2011 (327 cases from 10 pediatric oncology centers, and 867 matched 
control children) to investigate a proposed association between self-reported folic 
acid use (before and during pregnancy) and childhood brain tumors. Contrary to our 
findings, the authors found an inverse association of childhood brain tumors and 
maternal folic acid use before and possibly during pregnancy (Milne et al. 2012). The 
strengths of this study were the large sample size for main and subgroup analyses, 
information about preconception and postconception exposures, and sufficient data to 
conduct sensitivity analyses. Weaknesses were possible recall and selection biases, 
and lack of specificity in type and dose of vitamins and other minerals. Similarly, a 
recent multinational case-control study on childhood brain tumors in Denmark, 
Sweden, Norway and Switzerland (CEFALO), which included interviews with 352 
mothers of eligible cases and 646 population-based controls with data from birth 
registries, showed an inverse association between self-reported maternal vitamin 
intake during pregnancy and childhood brain tumor risk (Vienneau et al. 2016).  
Due to limited statistical power, we could not stratify our exposure data into 
preconceptional use and use during pregnancy. However, in line with our findings of 
no relation between maternal folic acid use and childhood brain tumors, a population-
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based case-control study from France (510 cases and 3,102 matched controls aged 
under 15 years) found no association between folic acid supplement intake and 
childhood brain tumor risk (Bailey et al. 2017). However, a weakness of this study 
was low use of folic acid supplements before conception (5.3% for cases and 7.8% 
for controls). 
Our analyses were further limited by a relatively short follow-up period. A longer 
observation time would have increased the number of study participants and the 
number of childhood cancer cases, thus increasing the statistical power of our 
analyses. The exposure information regarding folic acid intake during pregnancy that 
was available to us could have been more detailed regarding dose, frequency, and 
precise duration of use. However, we combined information on multivitamin and 
folic acid supplement use to establish exposure categories of increasing folic acid 
intake (0, ~0.2 mg, 0.4 mg, ~0.6 mg).  
Maternal smoking information was missing for 16% of the pregnancies. However, the 
association between periconceptional folic acid exposure and childhood cancer risk 
where essentially similar when the variable for maternal smoking was not included in 
our models. A similar finding is supported by a cohort study comprising 801,867 
children in Denmark, showing no association between maternal smoking during 
pregnancy and overall childhood cancer risk (Momen et al. 2016). 
Childhood cancer is a heterogenic group of rare malignancies that is different from 
adult cancers, and seems to originate in utero (Bjørge et al. 2013, Stiller 2004). Even 
when they are apparently similar to adult cancers like leukemia, lymphomas, brain 
tumors and other solid tumors, childhood cancer differ in underlying pathology, 
behavior and treatment outcome compared to the commonly occurring cancers of 
middle and old age (Murphy et al. 2013). Compared to adults, where carcinomas are 
the most common type, usually occurring during middle or old age, childhood 
cancers are predominantly embryonal tumors, and some sarcomas and germ-cell 
tumors, appearing at a young age (Steliarova-Foucher et al. 2005). The etiology is 
largely unknown, and a complex interplay of genetic, nutritional, hormonal, and 
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environmental factors has been associated with some childhood cancer types (Callan 
and Milne 2009). 
Based on the substantial role of folate in DNA methylation and nucleotide 
biosynthesis, dysregulation of DNA methylation in utero and in the early postnatal 
period may be one of many underlying mechanisms by which maternal 
periconceptional and postnatal nutrition can modulate childhood cancer risk (Kim 
2016, Ly et al. 2012). It is hypothesized that during the embryonic stage, DNA 
methylation is reprogrammed and maintained during the postnatal period, rendering it 
susceptible to the in utero and early postnatal nutritional environment (Kim 2016, Ly 
et al. 2012). Moreover, a study showed that blood folate concentration is inversely 
associated with DNA methylation, and that low folate at conception may act as a 
limiting factor on DNA methylation, but only below a certain threshold (200 μg/d) 
(Gonseth et al. 2015). The authors hypothesize that early-onset cancers like ALL may 
be triggered by low folate status through DNA methylation mechanisms (Gonseth et 
al. 2015).   
Ecological studies from countries with mandatory folic acid food fortification have 
shown a reduced incidence of certain childhood cancers, and several case-control 
studies suggest a possible protective association of periconceptional maternal folic 
acid use in relation to major childhood cancer types. Our population-based study of 
maternal periconceptional folic acid use and childhood cancer risk showed no 
relationship between maternal folic acid supplementation and major childhood 
cancers. On the other hand, we cannot assess the long-term childhood cancer risk 
after folic acid exposure in utero. 
5.2.3 Paternal characteristics associated with maternal 
periconceptional folic acid supplementation (publication III) 
To our knowledge, few studies have identified paternal determinants for maternal 
folic acid intake before and during pregnancy. Our analyses showed that fathers at 
younger and older age, compared to those aged 30–34 years at childbirth were 
associated with inadequate folic acid supplementation. There was a relationship 
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between the father completing only compulsory education, compared to tertiary 
education, and inadequate folic acid supplementation. Fathers in a manual or self-
employed occupation compared with the reference “Lower professionals,” and fathers 
who were born in low/middle-income countries compared to fathers born in Norway, 
were associated with inadequate folic acid supplementation. 
While our study focuses on paternal determinants of adequate maternal folic acid use, 
numerous studies have shown that younger maternal age is a significant determinant 
of inadequate folic acid use (R. M. Nilsen et al. 2016, Nilsen et al. 2006, 
Timmermans et al. 2008, Tort et al. 2013). This is consistent with our findings of 
younger paternal age as a risk factor for inadequate folic acid use. In contrast to these 
studies, we found low maternal use of folic acid among fathers at advanced age. Men 
are able to reproduce later in life than women; available data from the Nordic 
countries, Australia, England, Wales, and France, suggest that about 10% of fathers 
commence fatherhood in their 40s, and a smaller proportion have children after 50 
years of age (Schmidt et al. 2012). Concurrent to these data, the fathers were 40 years 
and older in 12% of the births in our study population.  
A previous study comprising about 27% of the births registered in the Medical Birth 
Registry of Norway during 2000–03 on the relationship between recommended 
maternal periconceptional supplementation and partner’s education align well with 
our results (Nilsen et al. 2006). The study found a positive association between 
paternal education and recommended periconceptional folic acid use. Nilsen and 
colleagues showed that in pregnancies with fathers having university or college 
education, the adjusted relative risk (RR) of periconceptional maternal folic acid use 
was 1.4 (95% CI 1.1‒1.8) compared to pregnancies with fathers having primary 
education only (Nilsen et al. 2006). However, the association was weaker than for 
maternal education. Similar results to ours have also been found among married 
Pakistani women, showing that the educational status of the mother’s husband is 
associated with maternal intake of iron and folic acid supplements (Nisar et al. 2014). 
Inadequate supplement use was strongly related to low paternal education. 
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A cross-sectional study (5,153 women extracted from the National Birth Defects 
Prevention Study in the US) of folic acid use, prenatal care, smoking, and drinking in 
early pregnancy by maternal occupation identified several occupational groups with 
increased prevalence of high-risk maternal behavior (smoking, alcohol consumption, 
or not attending prenatal care) or low use of folic acid supplements during pregnancy 
(Agopian et al. 2012). The occupational groups in which the women were less likely 
to use folic acid were “healthcare support,” “protective service,” “food 
preparation/serving-related,” “building and grounds cleaning/maintenance,” “sales 
and related,” “farming/fishing/forestry,” “production,” and “transportation/material 
moving”. These findings seem to be in line with our findings that occupational 
classes other than “higher professionals” among fathers were related to decreased risk 
of adequate folic acid supplement use.  
Studies on the relationship between women’s ethnic background and recommended 
periconceptional folic acid supplementation have been performed in Norway and 
other European countries (Netherlands, Belgium, Ireland and the United Kingdom) 
(Baraka et al. 2011, Brough et al. 2009, Kinnunen et al. 2017, McGuire et al. 2010, 
Timmermans et al. 2008). These studies have similar findings to our own, showing a 
low risk of adequate maternal periconceptional folic acid use among ethnic minority 
groups compared to the native population. 
Our investigation showed that periconceptional folic acid supplement use was still 
infrequent in Norway. During 1999–2010, the mothers used the recommended folic 
acid supplements for only 16% of the births in our study. Similar results have been 
found in Denmark. A cross-sectional study consisting of 22,000 pregnant women 
(primiparious and multiparous) during 2000–2002 showed that only 14% of them 
used folic acid as recommended (Knudsen et al. 2004). However, by 2012, only 
10.4% of 462 women attending a nuchal translucency scan in Demark used folic acid 
as recommended (Friberg and Jorgensen 2015). 
Education is the basis for labor achievements, and if such achievements are relevant 
to health, education may also increase the ability to act in healthy ways based on 
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knowledge of health (Pampel et al. 2010). A population-based register study of all-
cause mortality in Norway during 1980–2003 for all Norwegian men and women 
born between 1950 and 1973 (aged 30–53 years) showed that mortality is lower 
among those who have, or have had, a well-educated partner than among those with a 
less educated partner, although one’s own education is more important (Kravdal 
2008). Similar findings are reported in a cross-sectional study of the association 
between spousal education and self-rated health among married men and women in 
the US, constituting 337,846 married individuals aged 25 years and older (Brown et 
al. 2014). Spousal education attenuated the association between individuals’ own 
education and self-rated health among married men and women. The results suggest 
that husbands’ level of education is more important for wives’ self-rated health than 
wives’ level of education is for husbands’ self-rated health. Further, a Dutch cross-
sectional study of 40,000 individuals aged 25–74 years on the importance of partner 
status and education, showed that women appear to be more dominated by their 
partner’s educational level than men are with regard to healthy behavior (Monden et 
al. 2003). However, the evidence for male dominance in their study was weak.  
A cross-sectional study of data from the 2011–2013 National Survey of Family 
Growth in the US (2,089 pregnant women with a partner aged 18–49 years) examined 
the relationship between paternal pregnancy intention and breastfeeding duration. 
They found that unwanted pregnancy, specifically among fathers aged 18–24 years, 
was associated with no breastfeeding or shorter breastfeeding duration (Wallenborn et 
al. 2017). This result suggests a lack of support from fathers who do not want a 
pregnancy. Similar associations of paternal support and breastfeeding outcomes have 
been found in other studies (Bronte‐Tinkew et al. 2007, Tohotoa et al. 2009). 
Moreover, previous research on men’s birth intentions in the 2006–2010 National 
Survey of Family Growth study in the US reported that 63% of pregnancies were 
wanted by the father (Lindberg and Kost 2014). Further, a study on rapid repeat 
pregnancies in the US reported that the odds of having a rapid pregnancy after a 
previous one was higher when the father intended pregnancy but not the mother, and 
lower if the father did not intend pregnancy but the mother did (Cha et al. 2016). The 
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relevance of these findings is that men’s intention status of births influences their 
parental involvement and attitudes toward fertility-related behaviors (Lindberg et al. 
2017). 
In summary, these studies demonstrate the importance of the partner’s influence on 
maternal reproductive health and family planning. Our findings may support the 
importance of the father’s influence on maternal periconceptional folic acid 
supplementation.  
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6. Conclusions  
In this thesis, the access to data from population-based registries enabled us to study 
the association between folic acid and multivitamin supplementation in pregnancy 
and cancer risk in presumably healthy women and their children. Furthermore, we 
studied several potential paternal indicators of maternal periconceptional folic acid 
supplementation. Based on the results of our study, we reached the following 
conclusions:  
Folic acid supplementation does not increase the short-term overall cancer risk or risk 
of particular types of cancer among women using folic acid before and/or during 
pregnancy. 
Maternal folic acid supplementation use before and/or during pregnancy was not 
associated with risk of childhood leukemia, lymphomas, central nervous system 
tumors, neuroblastoma, Wilms’ tumor, or soft-tissue tumors. Although our cohort 
was observed over an average period of 6 years, the association between 
periconceptional folic acid exposure in utero and childhood cancer can only be 
addressed for young children.  
In general, this study highlights how the partner’s age, education, occupation and 
country of birth influences a woman’s use of recommended folic acid supplements. 
We found low maternal compliance to recommended periconceptional folic acid use 
in pregnancies when the fathers were among the youngest and oldest, had a shorter 
education, worked in a manual or self-employed occupation, or were born in 
low/middle-income countries.  
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7. Future perspectives 
Although our analyses address the short-term relationship between folic acid 
supplementation and cancer, we cannot assess the long-term effect of folic acid use 
on maternal or childhood cancer risk.  
The role of folates in cancer biology remains to be clearly defined. There is evidence 
that various adult and childhood cancers have different associations with folates. In 
order to determine the long-term risk of folic acid supplementation, a cohort study 
with extended follow-up is necessary to determine the risk and rate of progression 
from exposure to cancer for total and subgroups of adult and childhood cancers. 
When stratification of exposure data is not feasible due to the limited statistical power 
of the analyses, increasing the overall number of individuals will reduce data 
sparseness and improve precision. In order to achieve this in future studies, a 
considerably larger study population than ours is needed. 
A limitation of publications I and II is that there could be misclassification of 
maternal folic acid and multivitamin use. The information collected about folic acid 
use should be as detailed as possible, and thus future studies should include a 
renewed validation study. Moreover, multivitamins sold over the counter during our 
study period contained 0.0–0.2 mg of folic acid. A future study should also have 
information on folic acid doses in multivitamins.  
Lastly, studies highlight paternal influence in reproductive decisions, and couples 
tend to postpone parenthood. A future study of men’s birth intentions could focus on 
advanced paternal age (more than 35 years), socioeconomic status, maternal 




Publication I:  
The fourth sentence in 2.2 Exposure (Material and methods) on page 806: 
Furthermore, the mothers were defined as multivitamin users if folic acid were used 
before and/or during pregnancy. Should read: Furthermore, the mothers were defined 
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9.2 Appendix 2. Directed acyclic graphs (DAGs) 
(Publication III) 
Paternal health-related factors as exposition and maternal periconceptional folic acid 
use as an outcome. 
Association between paternal age and maternal periconceptional folic 
acid use 
 
We claim an association between “Father’s age” and “Maternal folic acid use” that is 
represented by an open “causal” path in green. Moreover, father’s age is related to 
father’s education, father’s occupation, and maternal folic acid use by open paths in 
green. Father’s education is also related to father’s occupation and maternal folic acid 
use by biasing paths in red. Father’s country of origin is related to father’s 
occupation, father’s education, and maternal folic acid use by biasing paths in red. 
Year of childbirth is related to father’s education, father’s occupation, father’s age, 
father’s country of origin, and maternal folic acid use by biasing paths in red. By 
using DAGitty (Textor et al. 2011), we identify year of childbirth as the minimal 
sufficient adjustment variable. 
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Association between paternal education and maternal periconceptional 





















We claim an association between “Father’s education” and “Maternal folic acid use,” 
which is represented by an open “causal” path in green. Father’s education is further 
related to father’s occupation by an open path in green. Father’s age is related to 
father’s education, father’s occupation, and maternal folic acid use by biased paths in 
red. Further, father’s country of origin is related to father’s occupation, father’s 
education, and maternal folic acid use by biasing paths in red. Year of childbirth is 
related to father’s occupation, father’s age, father’s country of origin, and maternal 
folic acid use by biasing paths in red. Using DAGitty (Textor et al. 2011), we identify 
father’s age, father’s country of origin, and year of childbirth as the minimal 




Association between paternal occupation and maternal periconceptional 
folic acid use 
 
We claim an association between “Father’s occupation” and “Maternal folic acid 
use,” which is represented by an open “causal” path in green. Father’s education is 
further related to father’s occupation and maternal folic acid use by biased paths in 
red. Father’s age is further related to father’s education, father’s occupation, and 
maternal folic acid use by biased paths in red. Moreover, father’s country of origin is 
related to father’s occupation, father’s education, and maternal folic acid use by 
biasing paths in red. Year of childbirth is further related to father’s occupation, 
father’s age, father’s country of origin, and maternal folic acid use by biasing paths in 
red. Using DAGitty (Textor et al. 2011), we identify father’s age, father’s education, 
father’s country of origin, and year of childbirth as the minimal sufficient adjustment 
variables.  
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Association between paternal country of origin and maternal 
periconceptional folic acid use 
 
We claim an association between “Father’s country of origin” and “Maternal folic 
acid use,” which is represented by an open “causal” path in green. Moreover, father’s 
country of origin is related to father’s occupation, father’s education, and maternal 
folic acid use by open paths in green. Father’s education is further related to father’s 
occupation and maternal folic acid use by biased paths in red. Father’s age is further 
related to father’s education, father’s occupation, and maternal folic acid use by 
biased paths in red. Year of childbirth is further related to father’s occupation, 
father’s age, father’s country of origin, and maternal folic acid use by biasing paths in 
red. By using DAGitty (Textor et al. 2011), we identify year of childbirth as the 
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A B S T R A C T
Background: There is evidence that increased intake of folate protects against the development of several
types of cancer. Some studies have, however, raised concern about the safety of folate in relation to cancer
risk. Here we examined the risk of maternal cancer after intake of supplemental folic acid in pregnancy.
Methods: This is a population-based cohort study comprising 429,004 women with data from the Medical
Birth Registry of Norway, the Cancer Registry of Norway, and other national registries from 1999 to 2010.
Altogether 3781 cancer cases were identified during follow-up (average 7 years). Cox proportional
hazards regression models were used to estimate hazard ratios of maternal cancer according to folic acid
use prior to and during one or two or more pregnancies as compared to no supplement use.
Results: Folic acid supplementation use had no overall effect on cancer risk in women using folic acid
supplementation in one (HR 1.08; 95% CI 1.00–1.18) or two or more pregnancies (HR 1.06; 95% CI 0.91–
1.22) (ptrend = 0.12). Analyses of 13 cancer types revealed no associations between folic acid and cancer.
Conclusion: Folic acid supplementation before and during pregnancy had no overall effect on maternal
cancer risk.
Impact: Folic acid substitution before and/or during pregnancy does not increase the short-term overall
maternal cancer risk.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Pre-gestational intake of folic acid prevents neural tube defects
(NTDs) [1–3], and in many countries health authorities recommend
women planning pregnancy to take folic acid supplementation
before and during pregnancy [2]. Mandatory food fortification with
folic acid has been implemented in many countries but remains
controversial in others, with issues concerning cancer risk [4–7]. At
present, there is no mandatory folic acid food fortification in Norway.
The Norwegian National Nutrition Council recommends that all
womenwho are planningpregnancyorare likely to become pregnant
use 400 mg folic acid daily from one month before pregnancy
throughout the first three months of pregnancy [8].
Folates are a group of B-vitamins important in DNA synthesis,
replication, and genomic stability [9,10]. Folic acid is the synthetic
form of folate with a substantially higher bioavailability relative to
food folate [11]. Data from human studies suggests that
consumption of high doses of folic acid, or with the highest blood
folate concentrations, have a significantly reduced risk of
developing colon polyps or cancer [12]. However, an entirely
protective role for folate against carcinogenesis has been
questioned. Based on human and animal evidence Kim proposed
that folic acid supplementation may enhance colorectal carcino-
genesis in neoplastic foci whereas folate deficiency may have an
inhibitory effect [13]. Further, supraphysiologic doses of folic acid
may enhance the development of cancer in normal colorectal
mucosa, modest doses of folic acid may suppress, whereas folate
deficiency may predispose the normal mucosa to neoplastic
transformation [13]. So far, findings from epidemiologic studies
have not been consistent on the subject of folate and cancer risk. A
2013 meta-analysis of 13 randomized trials including
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Primary Care, University of Bergen, Kalfarveien 31, N-5018 Bergen, Norway.
E-mail address: jan.mortensen@igs.uib.no (J.H.S. Mortensen).
http://dx.doi.org/10.1016/j.canep.2015.10.009
1877-7821/ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cancer Epidemiology 39 (2015) 805–811
Contents lists available at ScienceDirect
Cancer Epidemiology
The International Journal of Cancer Epidemiology, Detection, and Prevention
journa l homepage: www.cancerepidemiology.net
50,000 individuals comparing folic acid use versus placebo to
prevent complications in cardiovascular disease, showed no
statistically significant association with total cancer or sub-types
of cancer [14].
No studies on periconceptional folic acid supplementation and
maternal cancer risk have previously been conducted except for a
randomized, double-blind study published in 2004 that later was
criticized for the statistical approach and study design [15,16].
In the Medical Birth Registry of Norway, folic acid supplemen-
tation use has been registered since 1998. The aim of this study was
to examine the subsequent risk of maternal cancer after intake of
supplemental folic acid in pregnancy.
2. Material and methods
2.1. Data sources
Using the unique personal identification number given to
citizens living in Norway, data was retrieved from the Norwegian
Central Population Registry (NCPR) with linked data from the
Medical Birth Registry of Norway (MBRN) [17], the Cancer
Registry of Norway (CRN) [18], the Norwegian Labour and Welfare
Administration (NAV) and the Norwegian National Education
Database (NUDB). MBRN is a population-based registry contain-
ing information on all births in Norway since 1967 [17]. It is based
on compulsory notification of all deliveries from gestational week
16 (since 2002 from week 12). CRN was established in 1951 and
contains information on all new cancer cases and certain
precancerous lesions in Norway. NAV was established in
2006 after govermental reorganization of the Directorate of
Labour in Norway (founded in 1945), and holds information on
employment, health status and social benefits of all individuals
with residence in Norway since 1992. Since 1970, NUDB has
registered information on all individuals’ education since
completed primary school and as far as doctoral studies in one
database.
2.2. Exposure
The MBRN’s notification form from December 1998 onwards
has recorded information on folic acid and multivitamin supple-
mentation by using checkboxes with the items “folic acid before
pregnancy”, “folic acid during pregnancy”, “multivitamins before
pregnancy”, and “multivitamins during pregnancy”. In Norway,
folic acid supplements intended for use in pregnancy contained
0.4 mg folic acid, while most multivitamin supplements contained
0.0–0.2 mg of folic acid. The mothers were defined as folic acid
users if folic acid were used before and/or during pregnancy.
Furthermore, the mothers were defined as multivitamin users if
folic acid were used before and/or during pregnancy. Based on the
above information, we created two exposure variables of folic acid
use, and one exposure variable of multivitamin use; the use in
successive pregnancies (no use, use in one pregnancy, and use in
two or more pregnancies), and the total amount of folic acid from
multivitamin supplements (approximately 0.2 mg) and folic acid
supplements (0.4 mg).
2.3. Outcome
Incident cancer cases (International Classification of Diseases
version 10 (ICD-10)) were identified through linkage with CRN. For
each mother, only the first cancer diagnosis was used. The 13 most
frequent cancer sub-groups in our cohort were chosen. Sub-groups
of cancers included colorectal cancer (C18–21), lung cancer (C33–
34), melanoma of the skin (C43), non-melanoma skin cancer (C44),
breast cancer (C50), and cancer of the uterine cervix (C53), ovary
(C56), central nervous system (C70–72, D42–43), thyroid (C73),
and other endocrine glands (C37, C74–75), Hodgkin’s lymphoma
(C81), non-Hodgkin’s lymphoma (C82–85, C96), and leukemia
(C91–95, D45–47). Cancer sites with less than 50 cases were
combined in the group “Other cancers” (C00–17, C22–26, C30–32,
C38–41, C45, C47–49, C51–52, C54, C57–58, C64–69, C76, C80, C88,
C90).
2.4. Confounders
Data on maternal year of birth, maternal age at first childbirth in
the study period (1999–2010), maternal age at first childbirth
(prior to start of follow-up period), parity, marital status, and
smoking habits was collected from the MBRN. Information on
maternal smoking was recorded at start and end of pregnancy (no
smoking, sometimes, daily, number of cigarettes, declined to
inform about smoking habits). The smoking data was then
combined into a single variable that contained the maximum
cigarette consumption for each woman. Information on length of
education and occupation at time of childbirth was collected from
NUDB and NAV, respectively.
2.5. Study cohort
All women living in Norway and giving birth in the period
January 1, 1999 to December 31, 2010 (429,004 women and
679,484 pregnancies) constituted our study cohort. Induced
abortions (2491) were excluded since information on vitamin
use has not been registered. Pregnancies to women who emigrated
before birth (13,733) or women who were diagnosed with cancer
before delivery (3334) were also excluded. The women were
followed from the date of their first birth during 1999-2010 until a
cancer diagnosis, death, emigration, or end of follow-up at
December 31, 2010.
2.6. Statistical analysis
Hazard ratios (HRs) of cancer with 95% confidence intervals
(95% CIs), among women using folic acid in successive pregnancies
compared to women using no folic acid, were estimated using
time-dependent Cox proportional hazard regression models [19].
Time since the first childbirth during 1999–2010 was used as time
variable. Tests for linear trend over the categories of folic acid
supplementation were conducted.
Similar time-dependent Cox proportional hazard regression
analyses were also conducted for multivitamin use in successive
pregnancies compared to women using no multivitamins.
The Cox models were adjusted for maternal age at first
childbirth (age at cohort entry) during 1999–2010 (<20, 20–24,
25–29, 30–34, 35–39, 40 years), maternal year of birth (1949–59,
1960–69, 1970–79, 1980–89, 1990–96), and parity (1, 2, 3, 4),
marital status (unmarried, married/registered partner/cohabitant,
divorced/widowed), education (compulsory (1st–7th class level),
intermediate (8th–12th class level), tertiary (14th–20th class
level)), occupation (10 main groups), and smoking status at the
time of birth (never, sometimes, 10 cigarettes daily, >10 cigarettes
daily, daily smoking–unknown amount). For total cancer and
breast cancer, we also adjusted for maternal age at very first
childbirth (<20, 20–24, 25–29, 30–34, 35–39, 40 years).
For the years 2003–2010 occupational codes were available.
Occupational codes registered in 2003 were applied for births
during 1999–2002.
Since 16% of the study population had missing smoking
information, we performed multiple imputation on missing
smoking status at the time of birth according to White and
Royston [20], and Sterne and colleagues [21]. Time-dependent Cox
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Table 1
Characteristics of the study population at start of follow-up, Norway, 1999–2010.
Maternal characteristics Cohort Person-years % Cancer cases (n) %
Mothers 429,004 2,933,587 100 3781 100
Maternal year of birth
1949–59 3158 31,900 1 119 3
1960–69 102,284 920,987 31 1813 48
1970–79 227,841 1,621,811 55 1640 43
1980–89 92,535 355,060 12 208 6
1990–96 3186 3829 0 1 0
Maternal age at first childbirth in 1999–2010
<20 years 15,119 92,407 3 45 1
20–24 years 79,225 504,471 17 344 9
25–29 years 146,380 1,013,239 35 984 26
30–34 years 124,835 890,856 30 1361 36
35–39 years 52,931 365,858 12 823 22
40 10,514 66,755 2 224 6
Maternal age at first childbirtha
<20 years 33,626 249,038 8 256 7
20–24 years 122,114 885,507 30 916 24
25–29 years 150,240 1,054,830 36 1317 35
30–34 years 78,821 497,201 17 822 22
35–39 years 21,343 120,523 4 275 7
40 years 3,105 15,631 1 59 2
Missing data 19,755 110,857 4 136 4
Folic acid use in pregnancyb
No usec 252,620 2,002,547 68 2579 68
Before pregnancy 5082 31,153 1 32 1
During pregnancy 112,874 622,961 21 801 21
Before and during pregnancy 58,428 276,926 9 369 10
Multivitamin use in pregnancyb,d
No usec 298,543 2,187,443 75 2,826 75
Before pregnancy 5,890 33,067 1 53 1
During pregnancy 79,995 467,255 16 564 15
Before and during pregnancy 44,576 245,821 8 338 9
Educationb
Compulsory (1st–7th class level) 86,530 604,712 21 692 18
Intermediate (8th–12th class level) 149,530 1,093,481 37 1418 38
Tertiary (13th–20th class level) 174,222 1,133,166 39 1571 42
Missing data 18,722 102,227 3 100 3
Occupationb,e
Armed forces and unspecified 144,109 1,154,409 39 1516 40
Legislators, senior officials and managers 11,397 75,386 3 124 3
Professionals 21,543 118,501 4 192 5
Technicians and associate professionals 61,202 353,946 12 464 12
Clerks 27,314 192,749 7 268 7
Service workers and shop and market sales workers 97,772 605,065 21 639 17
Agricultural, forestry and fishery workers 1443 9766 0 8 0
Craft and related trades workers 4175 26,800 1 46 1
Plant and machine operators and assemblers 8732 59,862 2 63 2
Elementary occupations 19,164 127,270 4 114 3
Missing data 32,153 209,833 7 347 9
Parityb
1 278,438 1,631,675 56 1751 46
2 86,528 750,522 26 1110 29
3 45,168 391,057 13 644 17
4 18,870 160,333 5 276 7
Marital statusb
Unmarried 33,345 200,844 7 214 6
Married/partnership 385,481 2,644,365 90 3449 91
Divorced 2322 16,564 1 24 1
Missing data 7856 71,814 2 94 2
Smokingb
Never 275,462 1,885,522 64 2416 64
Sometimes 12,245 85,200 3 115 3
10 cigarettes daily 49,956 367,012 13 520 14
>10 cigarettes daily 18,304 117,721 4 151 4
Daily, unknown amount 4061 27,608 1 23 1
Missing data 68,976 450,524 15 556 15
a Including births before 1999.
b At start of follow-up.
c No information on use.
d Multivitamins used in Norway contain on average 0.2 mg folic acid.
e Occupational codes registered in 2003 were applied for births during 1999–2002.
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proportional hazard regression analyses were then conducted on
the imputed data set.
The statistical analyses were carried out with the statistical
packages SPSS version 22 and STATA version 13 [22,23].
3. Results
The women were followed for an average of 7 years (range 0.04–
12 years), constituting 2,933,587 person-years. The mean age at
start of follow-up was 29 years (range 13–54 years). Characteristics
of the study population at start of follow-up are presented in
Table 1.
During follow-up, 3781 cancer cases were diagnosed. The mean
age at diagnosis was 37 years (range 18–56 years). Mean time
between the first birth in the study period and cancer diagnosis
was five years (range 0.1–12 years). Breast cancer was the most
frequent cancer type in the cohort (1166 cases). A total of
343 cancer cases were grouped into the “Other” category when
the cancer site frequency was less than 50 cases. Table 2 shows
maternal age and year of primary cancer diagnosis.
Fig. 1 shows the use of supplements (folic acid, multivitamins)
and smoking related to pregnancy from 1999 to the end of the
study period in 2010. In 1999, only 18% of the women used folic
acid in pregnancy compared to 71% in 2010. Multivitamin use
increased from 19% in 1999 to 42% in 2010. Daily and intermittent
smoking registered among women in our cohort decreased from
26% in 1999 to 20% in 2010.
The adjusted HRs of cancer (total and sub-types) with 95 %
CIs by folic acid use (before and/or during pregnancy) in one
and two or more pregnancies compared to no folic acid use
during the study period are presented in Table 3. No increased
risk was seen for total cancer among women using folic acid in
one (HR 1.08; 95% CI 1.00–1.18) or two or more pregnancies (HR
1.06; 95% CI 0.91–1.22) (ptrend = 0.12), and other sub-types of
cancer, except for an increased risk for lung and trachea cancer
(ptrend = 0.06) and thyroid cancer (ptrend = 0.05) of borderline
significance.
Further adjustments for multivitamin use (in the analyses of
folic acid use) showed no substantial changes in the risk estimates,
neither for total cancer nor specific sub-types (data not shown).
Analyses of total dose of folic acid (continuous variable) ingested
from multivitamin supplements (0.2 mg folic acid) and folic acid
supplements (0.4 mg folic acid) revealed no substantial changes in
the risk estimates, neither for total cancer nor specific sub-types
(data not shown).
Multivitamin use (before and/or during pregnancy) in one, or
two or more pregnancies compared to no multivitamin use were
not associated with increased risk of total cancers. However,
increased risk was seen for melanoma of the skin among women
using multivitamins in one (HR 1.19; 95% CI: 0.96–1.48), and two
or more pregnancies (HR 1.58; 95% CI: 1.05–2.38) (ptrend = 0.02).
Additionally, increased risk of non-Hodgkin’s lymphoma was
seen among multivitamin users in one (HR 1.54; 95% CI: 0.94–2.53)
and two or more pregnancies (HR 2.82; 95% CI: 1.15–6.95)
(ptrend = 0.01).
Imputed analyses (on missing smoking data) showed no
substantial changes in the risk estimates, neither for total cancer
nor specific sub-types (data not shown).
4. Discussion
The aim of this study was to evaluate the association between
the recommended folic acid supplementation use and cancer risk.
Our population-based cohort study comprising 429,004 women
with data from the national registries in Norway, showed no
significant relationship between periconceptional folic acid use
and cancer risk.
Table 2
Cancer cases registered during follow-up (1999–2010) according to age at diagnosis
and calendar year among 429,004 women in Norway.
Cancer cases (n) %
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Fig. 1. Percentage folic acid (before and/or during pregnancy), multivitamin (before and/or during pregnancy) and cigarette use (intermittent or daily before/during
pregnancy) among 679,484 pregnancies in Norway, 1999–2010.
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Table 3
Hazard ratios (HR) of cancer with 95% confidence intervals (95% CI) by folic acid supplementation in one, or two or more pregnancies among 429,004 women in Norway,
1999–2010.
Cancer types ICD-10 codes Number of pregnancies with folic acid use Cancer cases
(N)
Model 1 Model 2
HR CI95% ptrend HR CI95% ptrend
Total cancer 0 2269 1.00 Reference 1.00 Reference
1 1214 1.09 1.01–1.17 1.08 1.00–1.18
2 298 1.04 0.92–1.17 0.08 1.06 0.91–1.22 0.12
Colorectal C18–21 0 98 1.00 Reference 1.00 Reference
1 52 1.11 0.79–1.56 0.91 0.60–1.38
2 19 1.75 1.06–2.90 0.06 1.96 1.10–3.50 0.16
Lung and trachea C33–34 0 31 1.00 Reference 1.00 Reference
1 17 1.20 0.66–2.17 1.69 0.82–3.48
2 6 1.80 0.74–4.39 0.21 2.41 0.83–7.01 0.06
Melanoma of the skin C43 0 275 1.00 Reference 1.00 Reference
1 164 1.18 0.97–1.43 1.08 0.87–1.35
2 55 1.52 1.13–2.04 0.00 1.35 0.96–1.89 0.11
Skin, non-melanoma C44 0 34 1.00 Reference 1.00 Reference
1 16 0.98 0.54–1.78 0.79 0.39–1.63
2 1 0.26 0.04–1.92 0.31 0.29 0.04–2.17 0.20
Breast C50 0 728 1.00 Reference 1.00 Reference
1 356 1.07 0.94–1.21 1.10 0.94–1.28
2 82 0.95 0.75–1.20 0.80 0.96 0.73–1.27 0.62
Cervix uteri C53 0 269 1.00 Reference 1.00 Reference
1 151 1.09 0.89–1.33 1.06 0.83–1.34
2 37 0.93 0.66–1.32 0.85 0.93 0.63–1.39 0.99
Ovary C56 0 48 1.00 Reference 1.00 Reference
1 23 0.95 0.58–1.56 1.04 0.58–1.86
2 3 0.57 0.17–1.84 0.43 0.90 0.26–3.10 0.99
Central nervous system C70-72, D42-43 0 208 1.00 Reference 1.00 Reference
1 121 1.15 0.92–1.44 1.13 0.86–1.47
2 28 1.04 0.70–1.56 0.40 0.97 0.61–1.53 0.72
Thyroid C73 0 138 1.00 Reference 1.00 Reference
1 84 1.17 0.89–1.54 1.36 0.99–1.86
2 30 1.57 1.05–2.35 0.03 1.41 0.88–2.26 0.05
Other endocrine glands C37, C74–75 0 59 1.00 Reference 1.00 Reference
1 28 0.92 0.59–1.45 0.80 0.46–1.38
2 4 0.48 0.17–1.34 0.22 0.54 0.19–1.58 0.20
Hodgkin’s lymphoma C81 0 44 1.00 Reference 1.00 Reference
1 34 1.46 0.93–2.28 1.34 0.81–2.23
2 6 1.00 0.42–2.38 0.34 0.78 0.29–2.10 0.79
Non-Hodgkin’s lymphoma C82–85, C96 0 54 1.00 Reference 1.00 Reference
1 34 1.18 0.77–1.82 1.24 0.75–2.05
2 5 0.90 0.36–2.29 0.72 1.00 0.37–2.67 0.61
Leukaemia C91–95, D45–47 0 60 1.00 Reference 1.00 Reference
1 31 1.05 0.68–1.62 1.19 0.71–2.00
2 5 0.74 0.29–1.86 0.76 0.65 0.19–2.18 0.96
Other cancers C00–17, C22–26, 0 223 1.00 Reference 1.00 Reference
C30–32, C38–41, 1 103 0.92 0.73–1.17 1.07 0.81–1.41
C45, C47–49, C51–52, 2 17 0.65 0.39–1.07 0.11 0.92 0.53–1.58 0.93
C54, C57–58, C64–69
C76, C80, C88, C90
Model 1: Adjusted for maternal age (<20, 20–24, 25–29, 30–34, 35–39, 40 years) at first childbirth in the study period 1999–2010.
Model 2: Further adjusted for maternal year of birth (1949–59, 1960–69, 1970–79, 1980–89, 1990–96), parity (1, 2, 3, 4), marital status (unmarried, married/registered
partner/cohabitant, divorced/widowed), education (compulsory [1st–7th class level], intermediate [8th–12th class level], tertiary [14th–20th class level]), occupation (armed
forces/unspecified, legislators, senior officials/managers, professionals, technicians/associate professionals, clerks, service workers/shop workers/market sales workers,
agricultural/forestry/fishery workers, craft/ related trades workers, plant/machine operators, assemblers/elementary occupations), and smoking (never, intermittent, 10
cigarettes daily, >10 cigarettes daily, daily smoking–unknown number of cigarettes). For total cancer and breast cancer the model was also adjusted for maternal age at first
childbirth (<20, 20–24, 25–29, 30–34, 35–39, 40 years) prior to start of follow-up.
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4.1. Comparisons with the literature
Our results are in accordance with several prospective cohort
studies and meta-analyses showing no overall or site-specific
association between folic acid use and cancer risk [14,24–26].
However, there are inconsistencies in the literature regarding
folate status and the risk of cancer. Some prospective cohort
studies have found an inverse association between dietary folate
intake or blood folate concentrations and risk of cancer of the
colon, breast, ovary, and pancreas [27–32]. Contrary to these
observational studies, two randomized controlled trials found no
protective association between folic acid use (in combination with
other B-vitamins) and cancer risk (overall and site-specific)
[24,25].
Several potential mechanisms have been proposed by which
folate or the bioactive form of folic acid may increase the risk of
cancer. Folate is important for the synthesis of DNA, methylation,
and repair [9,10]. An imbalance in these three functions might play
a role in carcinogenesis. Unmetabolized folic acid may compromise
the immunological defense against cancer and augment the
growth of established cancer cells [33]. Other reports suggest that
folic acid supplementation may promote cancer cells in already
established neoplastic foci through de novo methylation of tumor
suppressor genes with consequent gene inactivation, leading to
tumor progression [5,34].
Interestingly, a potential dual modulatory role of folate on
colorectal cancer has been proposed by Kim [13]. Folic acid may
enhance the growth of cancer cells in established neoplastic foci
whereas folate deficiency may inhibit progression of established
colorectal neoplasms. On the other hand, in normal colorectal
mucosa, folate deficiency may stimulate the initial stages of
carcinogenesis in the colon and rectum, moderate doses of folic
acid use may suppress, whereas high doses of folic acid may
enhance the development of cancer [13].
The complex relationship between folate intake and colorectal
cancer risk may be further modulated by genetic variants of folate
metabolism enzymes. The enzyme methylenetetrahydrofolate
reductase (MTHFR) is involved in the folate metabolism necessary
for both DNA methylation and DNA synthesis. A common
polymorphism in the MTHFR gene (MTHFR 677C!T polymor-
phism) is connected to reduced MTHFR enzyme activity and
function that is important for the nucleotide and methylation
pathways [35]. However, the MTHFR 677C!T polymorphism
appears to decrease the risk of several adult cancer types
(colorectal, liver, uterine cervical and acute lymphocytic leukemia)
[35]. The MTHFR 677 TT genotype seems, however, to increase the
risk of esophageal, gastric and pancreatic cancer [36].
We also evaluated the association between multivitamin use
and risk of cancer. Our finding of no association between
multivitamin use and total cancer risk is supported by other
studies, reporting little or no influence from multivitamin use on
total risk of cancer, including colorectal cancer [37,38]. Though, in
sub-group analyses we found an increased risk of malignant
melanoma and non-Hodgkin’s lymphoma. These findings are in
discrepancy with a large prospective cohort study on antioxidant
supplementation that did not show increased melanoma risk [39].
However, a study by Zhang et al. in 2001 showed that multivitamin
use was associated with a higher risk of non-Hodgkin’s lymphoma
among women, but not among men, and the authors concluded
that their observed findings were the results of chance [40].
4.2. Strengths and limitations
To our knowledge, this is the largest study on cancer risk and
folic acid use among pregnant women to date. The strengths of our
study are the large cohort consisting mainly of healthy women in
fertile age and the use of population-based registries covering the
entire Norwegian population, assuring generalizability of our
results. The loss to follow-up was minimal.
A limitation of this study is no records on dose, frequency, or
precise duration of folic acid or multivitamin use throughout
pregnancy. However, supplemental folic acid and multivitamin use
as recorded in the MBRN, has also been used in other epidemio-
logical studies [41,42]. In this study, we could not control for other
health behaviours than smoking. Consequently, there could be
confounding from other risk factors.
Altogether 16% of the pregnancies included in the study lacked
smoking data, but imputation of missing values for smoking did
not change our estimates. Most childbearing women know the
adverse health effects of smoking to the foetus, which could reduce
the reliance of self-reported smoking habits. On the other hand,
smoking habits were documented before a possible cancer
diagnosis.
Breast cancer was the most frequent cancer type in our cohort.
Since young women at first full-term pregnancy have a decreased
risk of developing hormone receptor positive breast cancer later
in life [43], we also adjusted risks of breast cancer and total cancer
for maternal age at her very first birth (including first birth before
cohort entry in 1999). Adjustments for other potentially
confounding factors (age at first childbirth in the study period,
maternal year of birth, marital status, occupation, and smoking)
showed minor changes in estimates, which reduced the likeli-
hood of residual confounding. But, we could not adjust for other
potential confounders, such as body mass index (BMI), physical
activity, diet, alcohol intake, use of NSAIDs, exogenous hormones,
and familial cancer syndromes, because these covariates were not
available. Alcohol use, known to antagonise folate absorption and
metabolism, is unlikely an important confounder, as the
consumption of alcohol during pregnancy is generally low in
Norway [44].
5. Conclusion
Overall, we found no association between folic acid supple-
mentation and cancer risk. Our study cannot, however, assess the
long-term impact of folic acid supplementation on cancer risk. The
complex biological relation between folate and cancer needs
cautious interpretation, and additional epidemiological research is
warranted.
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Background: We investigated the association between supplemental folic acid in pregnancy and childhood cancer in a nation-
wide study of 687 406 live births in Norway, 1999–2010, and 799 children diagnosed later with cancer.
Methods: Adjusted hazard ratios (HRs) compared cancer risk in children by approximated periconceptional folic acid levels (folic
acid tablets and multivitamins (0.6mg), only folic acid (0.4mg), only multivitamins (0.2mg)) and cancer risk in unexposed.
Results: Any folic acid levels were not associated with leukemia (e.g., high-level folic acid HR 1.25; 95% CI 0.89–1.76, PTrend 0.20),
lymphoma (HR 0.96; 95% CI 0.42–2.21, PTrend 0.51), central nervous system tumours (HR 0.68; 95% CI 0.42–1.10, PTrend 0.32),
neuroblastoma (HR 1.05; 95% CI 0.53–2.06, PTrend 0.85), Wilms’ tumour (HR 1.16; 95% CI 0.52–2.58, PTrend 0.76), or soft-tissue
tumours (HR 0.77; 95% CI 0.34–1.75, PTrend 0.90).
Conclusions: Folic acid supplementation was not associated with risk of major childhood cancers.
Health authorities in many countries recommend women planning
pregnancy to take folic acid before and during pregnancy to reduce
offspring risk of neural tube defects (SACN, 2006). A large number
of countries also fortify flour with folic acid (CDC, 2008).
Mandatory food fortification with folic acid is debated in some
countries because of the suggested cancer risk in adults (Kim, 2004;
Mason et al, 2007; Smith et al, 2008). However, in case–control
studies on children, cancer risks (leukemia, brain tumours) were
reduced if the mother had been exposed to perigestational
maternal folic acid supplementation (Thompson et al, 2001;
Milne et al, 2010; Milne et al, 2012; Metayer et al, 2014). And, in
ecological studies from Canada and the United States of America,
the childhood cancer incidence (Wilms’ tumour, primitive
neuroectodermal tumours, neuroblastoma) has been reduced
after mandatory folic acid flour fortification (French et al, 2003;
Grupp et al, 2011; Linabery et al, 2012).
The aim of our study was to investigate the association between
maternal intake of folic acid supplementation in pregnancy and
offspring risk of childhood cancer in a nation-wide cohort study in
Norway.
MATERIALS AND METHODS
Data sources. The unique personal identification number
assigned to all Norwegian residents enabled linkage of information
between the Medical Birth Registry of Norway (MBRN) (Irgens,
2000), the Cancer Registry of Norway (CRN) (Larsen et al, 2009),
and the Norwegian National Education Database that holds
information on all individuals’ education (Kinge et al, 2015).
Folic acid and multivitamin supplementation exposure. Folic
acid and multivitamin supplementation use has been registered in
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the MBRN since December 1998. The registration form uses check
boxes with the items ‘folic acid before pregnancy’, ‘folic acid during
pregnancy’, ‘multivitamins before pregnancy’, and ‘multivitamins
during pregnancy’. During the study period, the folic acid content
was 0.4mg in folic acid supplements and approximately 0.2mg in
multivitamin supplements. Children were defined as exposed to
folic acid if their mothers used folic acid supplements and/or
multivitamins before and/or during pregnancy. Maternal folic acid
intake was categorised by increasing folic acid content; no
supplement use (0mg), only multivitamins (approximately
0.2mg), only folic acid supplements (0.4mg), or intake of both
folic acid supplements and multivitamins (approximately 0.6mg).
Childhood cancer. Childhood cancer cases were identified through
linkage with CRN. For each child, the first cancer diagnosis was
used. The childhood cancers were categorised according to the
International Classification of Childhood Cancer, version 3, which is
based on ICD-O-3 (Steliarova-Foucher et al, 2005).
Study cohort. The study cohort consisted of all live births in
Norway, 1 January 1999 through 31 December 2010 (excluding
children with mothers with a prebirth cancer diagnosis (3371)),
with follow-up until a cancer diagnosis, emigration, death, or 31
December 2010.
Statistical analysis. Risk of childhood cancers in children exposed
to maternal folic acid and/or multivitamin supplements was
compared with cancer risk in unexposed children and estimated
with hazard ratios (HRs) using Cox proportional hazards
regression models with time since birth as the time variable,
adjusting for a priori selected covariates associated with maternal
folic acid use and childhood cancer risk; that is, birth order (1, 2,
X3), maternal smoking (never, sometimes, p10 cigarettes daily,
410 cigarettes daily, daily smoking of unknown amount),
maternal and paternal age (o25, 25–34, X35 years), and maternal
and paternal education (compulsory, intermediate, tertiary).
P-values for linear trend were calculated for folic acid exposure
levels (0mg, 0.2mg, 0.4mg, 0.6mg). Statistical analyses were
performed in STATA version 14 (STATA, 2015).
Ethics. The Regional Committee for Medical and Health Research
Ethics of Western Norway approved the study.
RESULTS
Among 687 406 children included in the study, 799 developed
cancer. The mean follow-up time was 6 years (range 0.04–12
years), constituting 4 052 679 person-years (Table 1). Among all
births, 4% were multiple births, and 2% were born after assisted
reproductive technology. Mean maternal age at childbirth was 29
years (range 13–55 years). The proportion of children exposed to
perigestational supplementation increased in the study period,
1999–2010; intake of folic acid changed from 18% to 69% and
multivitamins from 19% to 42%.
About 67% of all cancers were diagnosed within the first 3 years
of life (Table 2). Leukemia and central nervous system (CNS)
tumours accounted for 57% of the cases. We performed analyses
for the six most frequent childhood cancer types (leukemia,
lymphoma, CNS tumours, neuroblastoma, Wilms’ tumour, soft
tissue tumours) (Table 3). There was no change in childhood
leukemia risk by maternal use of multivitamins only (HR 1.23; 95%
CI 0.75–2.01), folic acid use only (HR 1.13; 95% CI 0.79–1.63), or
combined folic acid and multivitamin use (HR 1.25; 95%
CI 0.89–1.76), as compared with no supplement use (PTrend 0.20).
Similarly, there were no associations between CNS tumours and
different levels of maternal folic acid intake; multivitamins only
(HR 1.08; 95% CI 0.60–1.94), folic acid use only (HR 1.18; 95%
CI 0.78–1.78), or combined folic acid and multivitamin use
(HR 0.68; 95% CI 0.42–1.10), as compared with no supplement use
(PTrend 0.32). The HRs of the other frequent childhood cancer
types (lymphoma, neuroblastoma, Wilms’ tumour, soft tissue
tumours) did not change for different levels of folic acid exposure.
Adding birth year to adjustment models showed no substantial
Table 1. Characteristics of the study population of 687406






Children 687 406 4 052679 100 799
Sex
Boys 352 604 2 077322 51 423
Girls 334 802 1 975357 49 376
Gestational age (weeks)
o37 46682 271770 7 60
37–41 587197 3 447416 85 670
X42 48830 307613 8 62
Missing 4697 25881 1 7
Birth weight (g)
o2500 33804 191809 5 39
2500–3999 516075 3 008163 74 587
X4000 136760 847264 21 173
Missing 767 5443 0 0
Birth order
1 284468 1 651442 41 339
2 244834 1 446964 36 281
X3 158104 954274 24 179
Maternal age at child birth, years
o25 117065 697604 17 133
25–34 452481 2 709049 67 539
X35 117860 646026 16 127
Paternal age at child birth, years
o25 52776 312202 8 65
25–34 396496 2 406027 59 468
X35 231836 1 307428 32 257
Missing 6298 27023 1 9
Maternal educationa
Compulsory 128 452 782418 19 148
Intermediate 232 745 1 475123 36 288
Tertiary 299 871 1 662622 41 340
Missing 26338 132516 3 23
Paternal educationa
Compulsory 129 537 779208 19 142
Intermediate 301 918 1 842424 45 373
Tertiary 227 910 1 297762 32 251
Missing 28041 133286 3 33
Maternal smoking
Did not smoke 459617 2 678139 66 529
Smoked
sometimes
17 222 106380 3 15
Smoked p10
cigarettes daily
69 270 455935 11 103
Smoked 410
cigarettes daily
25 210 144005 4 30
Smoked daily,
unknown amount
5331 33502 1 4
Missing 110756 634718 16 118
Maternal supplementationb
No use 325706 2 307683 57 424
Multivitamins only 46 598 309597 8 61
Folic acid only 145 856 675461 17 154
Folic acid and
multivitamin use
169 246 759938 19 160
aCompulsory education length was 9 years until 1996 and 10 years from 1997 onwards.
bMaternal supplement intake before and/or during pregnancy, categorised by folic acid
content: No use; multivitamins (approximately 0.2mg); folic acid supplements (0.4mg); and
folic acid and multivitamins (approximately 0.6mg).
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changes in the risk estimates for neither cancer types. And
excluding 867 children with Down syndrome from the analyses did
not change the HR estimates for specific cancers.
DISCUSSION
In a nation-wide cohort study of all live births, estimated maternal
intakes of multivitamins, folic acid, or combined intake of these
supplements were not associated with childhood cancer.
Our results of no association between periconceptional folic acid
supplementation and major childhood cancers are in discordance
with case–control studies showing inverse associations between
self-reported folic acid use and acute lymphoblastic leukemia
(ALL) (Thompson et al, 2001; Milne et al, 2010; Metayer et al,
2014) and CNS tumours (Milne et al, 2012).
A recent large international collaborating study, including
47000 children with acute leukemia and 11 000 controls, found
reduced risks of ALL and acute myeloid leukemia (AML) after
maternal intake of folic acid supplements. And these reduced risks
of ALL and AML did not vary by timing of the supplementation
exposure (preconception, pregnancy, or pregnancy trimester)
(Metayer et al, 2014). However, an Australian study found weak
evidence of a reduced risk of ALL from folate supplementation
before pregnancy, but no reduced risk from use during pregnancy
(Milne et al, 2010). Also, another Australian study reported on an
inverse association of childhood brain tumours and folic
acid supplementation before and possibly also during pregnancy
(Milne et al, 2012). In our study, a further stratification of the
exposure data into preconceptional use and use during pregnancy
was not feasable due to the limited statistical power of the analyses.
The strengths of our study include using comprehensive data
from population-based registries covering the entire Norwegian
population. To our knowledge, Norway is the only country where
individual-level information on periconceptional folic acid and
multivitamin intake has been collected for the entire birth
population since 1999. All incident cancer cases have been
reported to the Cancer Registry of Norway since 1952 (Larsen
et al, 2009). And information on supplement use was collected
before cancer diagnosis precluding recall bias.
Table 2. Children with first-time childhood cancer (n¼799)
by age at diagnosis, year of diagnosis, and major cancer
types (ICCC-3), identified among 687406 livebirths, Norway,
1999–2010
Cancer cases %















Acute myeloid leukemias 45
II Lymphomas and reticuloendothelial
neoplasms
42 5





Intracranial and intraspinal embryonal
tumours
50
IV Neuroblastoma and other peripheral nervous
cell tumours
72 9
Neuroblastoma and ganglioneuroblastoma 71
VI Renal tumours 53 7
Wilms’ tumour 52
IX Soft tissue and other extraosseous sarcomas 64 8
Rhabdomyosarcoma 24
Other specified soft tissue sarcomas 28
Other cancers 115 14
Total 799 100
Abbreviations: CNS¼ central nervous system; ICCC-3¼ International Classification of
Childhood Cancer, third edition (Steliarova-Foucher et al, 2005).
Table 3. Hazard ratios (HRs) with 95% confidence intervals (95% CI) of childhood cancer by perigestational supplementation of
folic acid and/or multivitamins, among 687406 children, Norway, 1999–2010
Cancer types Supplementsa Cancer cases HRb 95% CI PTrend
All cancers No supplements 424 1.00 Reference
Multivitamins only 61 1.05 0.78–1.42
Folic acid only 154 1.13 0.92–1.38
Folic acid and multivitamins 160 1.02 0.83–1.25 0.60
I Leukemias, myeloproliferative diseases, and myelodysplastic diseases
No supplements 135 1.00 Reference
Multivitamins only 21 1.23 0.75–2.01
Folic acid only 50 1.13 0.79–1.63
Folic acid and multivitamins 62 1.25 0.89–1.76 0.20
(a) Lymphoid leukemia
No supplements 100 1.00 Reference
Multivitamins only 16 1.30 0.75–2.27
Folic acid only 42 1.30 0.87–1.95
Folic acid and multivitamins 50 1.31 0.89–1.94 0.12
(b) Acute myeloid leukemia
No supplements 28 1.00 Reference
Multivitamins only 3 0.97 0.29–3.27
Folic acid only 5 0.59 0.22–1.60
Folic acid and multivitamins 9 0.96 0.43–2.17 0.67
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The study had some limitations. Even though our cohort was large,
the numbers of several childhood cancer types were relatively low,
which may limit the statistical power of our findings. The follow-up
time of study participants were on average 6 years, and our results
could only be generalised to younger children. Maternal folic acid
intake could have been misclassified; in the beginning of the study
period, folic acid users were under-reported to the MBRN (Nilsen
et al, 2009). A possible misclassification of folic acid dose
(independent of cancer risk) would bias risk estimates towards the
null value and, in theory, could have concealed an association between
folic acid intake and childhood cancer risk. Information on maternal
smoking was missing for 16% of the births; however, HR estimates
adjusting for maternal smoking were similar to HRs without smoking
adjustments. Although we did not have information on dietary folate,
residual confounding by dietary folate is less likely. In pregnant
women, maternal plasma levels of serum folate is strongly related to
intake of folic acid supplements (Bjorke-Monsen et al, 2013). And in
other studies of maternal intake of folic acid supplements and
offspring outcomes (oral clefts, autism), adjustment for dietary folate
did not change overall risk estimates (Wilcox et al, 2007; Suren et al,
2013). We could not adjust for mother’s weight and height, physical
activity, diet, use of alcohol, or use of contraceptive pills, as these
covariates were not available in the MBRN.
In conclusion, we found no association between maternal
supplemental folic acid intake before and/or during pregnancy and
risk of leukemia, lymphomas, CNS tumours, neuroblastoma,
Wilms’ tumour, or soft tissue tumours among younger children.
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Table 3. ( Continued )
Cancer types Supplementsa Cancer cases HRb 95% CI PTrend
II Lymphomas and reticuloendothelial neoplasms
No supplements 25 1.00 Reference
Multivitamins only 3 0.55 0.13–2.33
Folic acid only 5 0.40 0.12–1.34
Folic acid and multivitamins 9 0.96 0.42–2.21 0.51
III CNS and miscellaneous intracranial and intraspinal neoplasms
No supplements 107 1.00 Reference
Multivitamins only 14 1.08 0.60–1.94
Folic acid only 37 1.18 0.78–1.78
Folic acid and multivitamins 27 0.68 0.42–1.10 0.32
(b) Astrocytoma
No supplements 44 1.00 Reference
Multivitamins only 8 1.57 0.72–3.40
Folic acid only 15 1.31 0.70–2.45
Folic acid and multivitamins 12 0.86 0.43–1.73 0.97
(c) Intracranial and intraspinal embryonal tumours
No supplements 28 1.00 Reference
Multivitamins only 2 0.61 0.14–2.59
Folic acid only 12 1.28 0.60–2.76
Folic acid and multivitamins 8 0.69 0.27–1.74 0.69
IV Neuroblastoma and other peripheral nervous cell tumours
(a) Neuroblastoma and ganglioneuroblastoma
No supplements 37 1.00 Reference
Multivitamins only 5 0.99 0.35–2.82
Folic acid only 15 1.08 0.54–2.15
Folic acid and multivitamins 14 1.05 0.53–2.06 0.85
VI Renal tumours
(a) Wilms’ tumour
No supplements 28 1.00 Reference
Multivitamins only 5 1.60 0.60–4.25
Folic acid only 9 1.01 0.42–2.40
Folic acid and multivitamins 10 1.16 0.52–2.58 0.76
IX Soft tissue and other extraosseous sarcomas
No supplements 32 1.00 Reference
Multivitamins only 5 1.12 0.39–3.22
Folic acid only 18 1.72 0.90–3.29
Folic acid and multivitamins 9 0.77 0.34–1.75 0.90
Abbreviation: CNS¼ central nervous system.
aMaternal supplement intake before and/or during pregnancy, categorised by folic acid content: No use; multivitamins (approximately 0.2mg); folic acid supplements (0.4mg); and folic acid
and multivitamins (approximately 0.6mg).
bHazard ratios (HR) with 95% confidence intervals (95% CI) adjusted for birth order (1, 2, X3), smoking (never, sometimes, p10 cigarettes daily, 410 cigarettes daily, daily smoking of unknown
amount), maternal and paternal age (o25, 25–34, X35 years), and maternal and paternal education (compulsory, intermediate, tertiary) comparing cancer risk in children exposed to
periconceptional folic acid (multivitamins, folic acid, folic acid and multivitamins) and cancer risk in children without perigestational folic acid exposure (reference).
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Abstract
Background: Maternal predictors of folic acid (FA) supplementation use to reduce offspring risk of neural
tube defects are well known, while paternal determinants for maternal FA use are less known. Such knowledge is
important to increase women’s compliance to recommended periconceptional FA use.
Methods: In a nation-wide study of 683,785 births registered in the Medical Birth Registry of Norway during
1999–2010, the associations between paternal characteristics (age, education, occupation, country of origin)
and maternal FA use were estimated by relative risks (RR) with 95% confidence intervals (CI), using log-
binomial regression.
Results: Maternal FA use before and during pregnancy (adequate FA use) was found in 16% of the births.
The association between paternal age and adequate FA use was inversely U-shaped; adjusted RRs for adequate FA use
were 0.35 (95% CI 0.28–0.43) and 0.72 (95% CI 0.71–0.74) for paternal age < 20 and≥ 40 years, respectively, comparing
age 30–34 years. Compulsory education (1–9 years) among fathers was compared to tertiary education; the RR was 0.69
(95% CI 0.68–0.71) for adequate FA use. The lower risk of adequate FA use for paternal compulsory education was present
in all categories of maternal education. Occupation classes other than “Higher professionals” were associated
with decreased risk of adequate FA use, compared with the reference “Lower professionals”. RR for adequate
FA use was 0.58 (95% CI 0.56–0.60) comparing fathers from “Low/middle-income countries” with fathers born
in Norway.
Conclusion: Adequate FA use in the periconceptional period was lower when fathers were younger or older
than 30–34 years, had shorter education, had manual or self-employed occupations, or originated from low/
middle-income countries. Partners may contribute to increase women’s use of periconceptional FA
supplementation.
Keywords: Pregnancy, Supplement use, Folic acid, Norway
Background
Folate is necessary in foetal development, and folic acid
(FA) supplementation is widely acknowledged to reduce
the risk of neural tube defects (NTDs) [1–5]. FA is the
synthetic form of the B-vitamin folate, which is essential
in the synthesis of DNA, methylation, and DNA repair
[6]. Start of FA supplementation prior to conceiving is
important in order to reduce the risk of NTDs because
the neural tube closes between 21 and 28 days after
conception [7].
Randomized clinical trials and non-randomized
intervention trials have demonstrated that periconcep-
tional FA use reduces the risk of NTDs [1–3]. Recent
studies have reported that FA is associated with protec-
tion against other neurodevelopmental disorders and
some severe pregnancy complications [8–10]. The pro-
tective effect of FA on NTDs has led health authorities
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in several countries, including Norway, to recommend
women to take FA supplements before pregnancy and in
early pregnancy [11–13].
Many countries in Europe, including Norway, have
performed information campaigns to increase the use of
periconceptional FA supplementation among women
planning pregnancy [14–16]. Presently there is no
mandatory folic acid food fortification in Norway [17].
Official Norwegian guidelines from 1998, states that all
women planning their pregnancy should use 0.4 mg FA
daily from 1 month before pregnancy and throughout
the first 2–3 months of pregnancy to reduce the risk of
NTDs [12]. However, the proportion of preconception
FA supplementation use in Norway is still too low [18]
and by 2015 it was 33% [19].
Previous studies have identified maternal factors
associated with inadequate FA in the periconceptional
period, such as low maternal age, shorter education,
single parenthood, unplanned pregnancy, lower parity,
smoking, alcohol use, less physical activity, or originating
from a foreign country [15, 16, 20–24].
Since couples tend to exhibit concordant health
behaviour’s for dietary intake, smoking, alcohol
consumption, physical activity, and body mass index
(BMI) [25–27], a woman’s partner may contribute to her
use of periconceptional FA supplements. In fact, in an
early report from the Norwegian Mother and Child
Cohort Study (MoBa), 2000–2003, counting 22,500
women, FA supplements were used more frequently
among women with partners with a higher education
[22]. However, the study did not assess other paternal
factors or combined paternal and maternal factors as to
identify women with inadequate FA use.
Taking advantage of the Medical Birth Registry of
Norway that to our knowledge is the only national regis-
try with information on periconceptional use of FA sup-
plements [28], we updated parent information with data
from national registries to investigate whether paternal
factors (age, education, occupation, country of origin)




Maternal FA use before and/or during pregnancy was
collected from the Medical Birth Registry of Norway
(MBRN) [28]. Paternal and maternal demographic data
came from the National Registry (NR). Information on
paternal and maternal occupation originated from the
Norwegian Labour and Welfare Administration (NAV),
and we retrieved paternal and maternal educational data
from the Norwegian National Education Database
(NUDB) [29].
MBRN is a population-based registry containing
information on all births in Norway since 1967 [28]. The
registry holds demographic information on the mother
and the father, the mother’s health before and during
pregnancy, including chronic diseases, information on in
vitro fertilization (IVF), complications during pregnancy
and delivery as well as information on the infant, includ-
ing birth defects and other perinatal problems. Midwives
and physicians attending the deliveries register the data.
Since 1967, there has been mandatory reporting of all
live and stillbirths from the 16 gestational week to
MBRN.
NR contains demographic information on all residents
in Norway since 1960, including the date of birth,
country of origin, and the dates of immigration, emigra-
tion, or death [30]. NR assigns a unique personal identi-
fication number to all individuals born or immigrated to
Norway, enabling accurate record linkages.
NAV was established in 2006 after governmental
reorganization of the Directorate of Labour in Norway
(founded in 1945), and has registered information on
occupation, health status, and social benefits of all indi-
viduals with residence in Norway since 1992. The
Norwegian occupational code system is based on the
International Standard Classification of Occupations
(ISCO), revised version from 1988 [31].
Since 1970, NUDB holds information on all individ-
uals’ education history from primary school up to
doctoral studies in one database [32]. The classification
is based on the Norwegian Standard Classification of
Education.
Maternal FA supplement use
We constructed a binary variable for intake of FA sup-
plement use (0.4 mg/day) (regardless of concomitant
multivitamin use) registered in the MBRN since Decem-
ber 1998 onwards; adequate FA use (recommended FA
supplementation before and during pregnancy), and in-
adequate FA use (FA supplementation only before preg-
nancy, or only during pregnancy, or no record of FA
use).
MBRN also registers multivitamin use, but our investi-
gation focused on periconceptional FA use as such in-
take was according to official guidelines.
Paternal characteristics
We used the following paternal variables in our
analyses of adequate FA supplementation; paternal
age (< 20, 20–24, 25–29, 30–34, 35–39, 40+ years);
education (Compulsory (1–9 years), Intermediate (10–
12 years), Tertiary (13–19 years)); occupation accord-
ing to the class scheme of Erikson, Goldthorpe, and
Portocarero (I Higher professionals, II Lower profes-
sionals, IIIa Higher routine, IIIb Lower routine, IV
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Other self-employed workers, V Technicians, VI
Skilled, VII Semiskilled and unskilled, VIIb Agricul-
tural, Unclassified) (EGP) [33]; and country of origin
according to the classification by World Health
Organization, Health statistics and information sys-
tems, Estimates for 2000–2012 (Norway, High income
countries, Low/middle-income countries) [34].
Covariates
We used directed acyclic graphs (DAGs) and
subject-matter knowledge to select a minimally sufficient
adjustment set of variables that identify the uncon-
founded association of paternal characteristics on ad-
equate maternal FA supplementation use [35–37].
The potential confounders of the paternal characteris-
tics and maternal FA use relationship included year of
childbirth (continuous), paternal age (< 20, 20–24, 25–
29, 30–34, 35–39, 40+ years), education (Compulsory,
Intermediate, Tertiary), or country of origin (Norway,
High-income countries, Low/middle-income countries).
Furthermore, we included maternal age (< 20, 20–24,
25–29, 30–34, 35–39, 40+ years), maternal education
(Compulsory, Intermediate, Tertiary), and maternal
country of origin (Norway, High-income countries, Low/
middle-income countries) as possible confounders of the
associations between paternal age, education, or country
of origin, and maternal adequate FA use.
Maternal smoking was not included in the final
models because smoking was not considered a con-
founder of the association of paternal characteristics on
maternal FA supplementation use [38].
Study population
During 1999–2010, 716,021 births were registered in
MBRN. We excluded births (induced abortions) without
information on FA or multivitamin supplementation use
(2519) and births without maternal identification num-
ber (4091). For multiple births, we included data for the
first birth and excluded 12,927 next born individuals.
Among the remaining 696,484 births, we excluded
12,699 births without paternal identification number,
leaving 683,785 live births and stillbirths for analyses.
Statistical analysis
Associations between paternal characteristics (age, edu-
cation, occupation, country of origin) and maternal FA
use were estimated as relative risks (RRs) with 95% con-
fidence intervals (CIs) by log-binomial regression, using
the log-link function in Stata version 15 [39]. The 95%
CIs were based on robust variance estimation with the
sandwich estimator to correct for the intra-individual
correlation in women with more than one pregnancy
during the study period [40]. Births with missing data on
covariates were excluded from the analyses. P-values for
overall difference between the categories of paternal
characteristics were calculated using likelihood ratio
tests. We evaluated and tested the potential effect modi-
fication of the association between paternal education
and maternal FA use by stratification and likelihood ra-
tio test.
Results
Our study included 683,785 births during 1999–2010.
Table 1 presents the characteristics of the parents. The
median ages of the fathers and mothers at childbirth
were 33 and 30 years, respectively. For about 41% of the
births, the mothers were primiparous, and about 2% of
the births were conceived after in vitro fertilization
(IVF). The majority of the births were of
Norwegian-born parents (84% of the fathers and 83% of
the mothers). For about 34% of the births, the fathers
had tertiary education, and for about 19% of the births,
the fathers had compulsory education only. The paternal
educational level varied by his country of origin. Fathers
originating from low/middle-income countries generally
had lower educational level compared to fathers origin-
ating from Norway and other high-income countries
(not shown). Occupation classified as “Lower profes-
sionals,” accounted for 22% of all the births. For about
14% of the births, the women smoked daily at the start
of pregnancy, about 3% smoked intermittently, and 67%
did not smoke. Nearly 17% of the smoking data were
missing.
For about 16% of all births in the study population,
the mothers were assigned to the category adequate FA
supplementation users. However, during 1999 through
2010, the proportion of adequate FA supplementation
use increased from 4% at the start of the study period
(1999) to 26% in 2010.
Table 2 presents crude and adjusted RRs for ad-
equate maternal periconceptional FA use by paternal
variables (determinants). Adjusted analyses showed an
inverse “U-shaped” relationship between paternal age
and adequate maternal FA supplement use where the
smallest RRs were found for paternal age below
20 years (RR 0.35 (95% CI 0.28–0.43)), 20–24 years
(RR 0.68 (95% CI 0.66–0.71)), and 40 years and above
(RR 0.72 (95% CI 0.71–0.74)) compared to paternal
age 30–34 years. Paternal compulsory education was
associated with reduced risk of adequate FA use (RR
0.69 (95% CI 0.68–0.71)) compared to paternal ter-
tiary education. All paternal occupation classes were
associated with reduced risk of adequate FA use ex-
cept for “I Higher professionals”, when compared to
“II Lower professionals”, in particular “VII Semiskilled
and unskilled” (RR 0.75 (95% CI 0.73–0.76)), and
“VIIb Agricultural” (RR 0.73 (95% CI 0.69–0.78)).
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Mothers whose children’s father originated from low/
middle-income countries had also a reduced risk of ad-
equate FA use (RR 0.58 (95% CI 0.56–0.60)) compared
to fathers originating from Norway.
Table 3 presents crude and adjusted RRs with 95% CIs
of adequate FA use by maternal and paternal education.
Adjusted analyses showed that adequate FA use was less
likely in births were fathers had compulsory education,
regardless of maternal education. The association of pa-
ternal compulsory education and recommended FA use
was weakened by increasing level of maternal education.
However, even when the mother had tertiary education,
the association of compulsory paternal education on ad-
equate maternal FA use was significant (RR 0.75 (95% CI
0.73–0.77)), compared to fathers with tertiary education.
Discussion
The present population-based study (683,785 births
during 1999–2010) showed that recommended maternal
FA use was low among fathers who were young or older
at their children’s birth, had achieved shorter education,
held a manually or self-employed occupation, or
originated from low/middle-income countries. Even
among mothers who had achieved higher education, rec-
ommended periconceptional maternal FA use was low
among less educated fathers.
Several studies have investigated the association be-
tween maternal socio-demographic, reproductive, and
medical characteristics and adherence to recommended
intake of periconceptional FA. A common feature among
mothers is that young age, low educational level, low
Table 1 Paternal and maternal characteristics in 683,785 births
in Norway, 1999–2010
Births
Fathers % Mothers %
Number of births 683,785 100.0 683,785 100.0
Age
< 20 4401 0.6 15,464 2.3
20–24 48,448 7.1 100,016 14.6
25–29 162,671 23.8 223,480 32.7
30–34 235,401 34.4 228,203 33.4
35–39 151,540 22.2 99,727 14.6
40+ 81,324 11.9 16,895 2.5
Education
Compulsory education (1–9 years) 130,953 19.2 125,479 18.4
Intermediate (10–12 years) 302,384 44.2 230,320 33.7
Tertiary education (13–19 years) 229,818 33.6 298,036 43.6
Missing data 20,630 3.0 29,950 4.4
Occupational class a
I Higher professionals 86,635 12.7 50,650 7.4
II Lower professionals 152,781 22.3 122,804 18.0
IIIa Higher routine 77,540 11.3 197,174 28.8
IIIb Lower routine 40,070 5.9 114,795 16.8
IV Other self-employed workers 358 0.1 119 0.0
V Technicians 5550 0.8 1492 0.2
VI Skilled 108,755 15.9 15,961 2.3
VII Semiskilled and unskilled 111,584 16.3 73,994 10.8
VIIb Agricultural 7663 1.1 2720 0.4
Unclassified 52,824 7.7 51,264 7.5
Missing data 40,025 5.9 52,812 7.7
Country of origin b
Norway 574,602 84.0 567,241 83.0
High income countries 33,487 4.9 30,920 4.5
Low/middle-income countries 75,497 11.0 85,597 12.5





Missing data 9028 1.3







Table 1 Paternal and maternal characteristics in 683,785 births
in Norway, 1999–2010 (Continued)
Maternal chronic disease c
No 623,817 91.2
Yes 59,968 8.8




Missing data 114,808 16.8
Maternal folic acid use in pregnancy
No use 371,820 54.4
Only before 8930 1.3
Only during 192,169 28.1
Before and during 110,866 16.2
aCategorized according to the class scheme of Erikson, Goldthorpe and
Portocarero (EGP) [33]
bCategorized according to the classification by World Health Organization,
Health statistics and information systems, Estimates for 2000–2012 [34]
cAsthma, hypertension, kidney disease, chronic urinary infection, rheumatoid
arthritis, heart disease, epilepsy, diabetes mellitus (type I or II), and
thyroid disease
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socioeconomic status, unplanned pregnancy, higher par-
ity, smoking, single marital status, and non-western
birthplace is the most important determinants for inad-
equate FA supplementation use [20–23]. Furthermore,
maternal chronic diseases and IVF were positively asso-
ciated with adequate periconceptional FA supplementa-
tion use [22, 38].
In Denmark, a cross-sectional study consisting of
22,000 pregnant women (primiparious and multipar-
ous) showed that only 14% of the women used FA as
recommended and compliance was positively associ-
ated with being primiparous, older than 25 years and
non-smoker [21]. Similarly, for about 16% of the
births in our study, the mothers had followed the
Table 2 Relative risks (RRs) with 95% confidence intervals (95% CIs) of adequate maternal periconceptional folic acid supplement
use (before and during pregnancy) by paternal characteristics, in 683,785 births, Norway, 1999–2010
Folic acid supplementation
use
Unadjusted Adjusted for paternal factors a b Further adjusted for maternal
factors a c
Characteristics Yes No RR* 95% CI RR* 95% CI RR* 95% CI
Paternal age (years)
< 20 86 4315 0.11 0.09–0.13 0.10 0.08–0.13 0.35 0.28–0.43
20–24 3325 45,123 0.37 0.36–0.39 0.37 0.36–0.38 0.68 0.66–0.71
25–29 22,886 139,785 0.76 0.75–0.78 0.77 0.76–0.79 0.94 0.93–0.96
30–34 43,348 192,053 1.00 Reference 1.00 Reference 1.00 Reference
35–39 28,488 123,052 1.02 1.01–1.03 0.97 0.96–0.99 0.90 0.89–0.91
40+ 12,733 68,591 0.85 0.83–0.87 0.80 0.78–0.81 0.72 0.71–0.74
Paternal education
Compulsory (1–10 years) 11,694 119,259 0.40 0.39–0.40 0.52 0.51–0.53 0.69 0.68–0.71
Intermediate (11–13 years) 45,411 256,973 0.67 0.66–0.67 0.75 0.74–0.76 0.87 0.85–0.88
Tertiary (14–20 years) 51,894 177,924 1.00 Reference 1.00 Reference 1.00 Reference
Missing data 1867 18,763
Paternal occupational class d
I Higher professionals 19,957 66,678 1.05 1.04–1.07 1.05 1.03–1.06
II Lower professionals 33,366 119,415 1.00 Reference 1.00 Reference
IIIa Higher routine 12,292 65,248 0.73 0.71–0.74 0.89 0.88–0.91
IIIb Lower routine 5352 34,718 0.61 0.59–0.63 0.85 0.83–0.87
IV Other self-employed workers 60 298 0.77 0.61–0.97 0.83 0.65–1.05
V Technicians 836 4714 0.69 0.65–0.74 0.89 0.84–0.95
VI Skilled 15,174 93,581 0.64 0.63–0.65 0.84 0.83–0.86
VII Semiskilled and unskilled 11,643 99,941 0.48 0.47–0.49 0.75 0.73–0.76
VIIb Agricultural 908 6755 0.54 0.51–0.58 0.73 0.69–0.78
Unclassified 7575 45,249 0.66 0.64–0.67 0.96 0.94–0.99
Missing data 3703 36,322
Paternal country of origin e
Norway 99,339 475,263 1.00 Reference 1.00 Reference 1.00 Reference
High income countries 6535 26,952 1.13 1.10–1.16 1.06 1.04–1.09 1.06 1.03–1.08
Low-middle-income countries 4975 70,522 0.38 0.37–0.39 0.35 0.34–0.36 0.58 0.56–0.60
Missing data 17 182
aAll RRs for adequate folic acid supplementation adjusted for year of childbirth (continuous)
bRRs by paternal age, no other adjustment for paternal factors; RRs by paternal education adjusted for paternal age (< 20, 20–24, 25–29, 30–34, 35–39, 40+),
paternal country of origin (Norway, high-income countries, low/middle-income countries); RRs by paternal occupation adjusted for paternal age, fathers country of
origin, fathers education (compulsory, intermediate, tertiary); and RR by paternal origin of country, no other adjustment for paternal factors
cRRs by paternal age, further adjusted for maternal age (< 20, 20–24, 25–29, 30–34, 35–39, 40+); RRs by paternal education, further adjusted for maternal
education (compulsory, intermediate, tertiary); RRs by paternal occupation, no further adjustment for maternal factors; RRs by paternal country of origin adjusted
for maternal country of origin (Norway, High-income countries, Low/middle-income countries)
dCategorized according to the class scheme of Erikson, Goldthorpe and Portocarero (EGP) [33]
eCategorized according to the classification by World Health Organization, Health statistics and information systems, Estimates for 2000–2012 [34]
*p-value for difference between categories of paternal characteristics was < 0.001 using likelihood ratio test
Mortensen et al. BMC Pregnancy and Childbirth  (2018) 18:188 Page 5 of 8
national guidelines of FA use in the study period
(1999–2010).
In Norway, a publication from the Norwegian Mother
and Child Cohort Study (MoBa), comprising 27% of the
births registered in MBRN during 2000–2003, showed
similar results to ours [22]. They found a positive associ-
ation between paternal education and recommended
periconceptional FA use. In pregnancies with fathers
having university or college education the adjusted rela-
tive risk (RR) of periconceptional maternal FA use was
1.4 (95% CI 1.1–1.8) compared to pregnancies with fa-
thers with primary education. However, the association
was weaker than for maternal education. When paternal
tertiary education was compared to paternal compulsory
education (reference) in our analyses, we found a similar
result for adjusted RR of 1.45 (95% CI 1.42–1.48).
Couples who live together share the same environ-
ment, social network, financial resources, and to some
extent, the same health risk; beneficial or negative to
health outcomes depending on the health behaviour of
the spouses [25, 27]. Furthermore, a Dutch study of
40,000 individuals aged 25–74 years showed that women
seems more affected by their partner’s educational level
than men are with regard to healthy behaviour [41].
In accordance with our findings, a cross-sectional
household survey conducted in Pakistan (comprising
6266 women), showed that maternal intake of iron and
FA supplements was positively associated with the edu-
cational status of the mothers’ husband [42].
The association of ethnic background and maternal
periconceptional FA use have been studied in Norway
and other European countries (Netherlands, Belgium,
Ireland and the United Kingdom) [23, 43–46]. These
studies show that supplement use is less common
among most ethnic minority groups than among the
comparison groups. We have similar findings in our
study, showing a lower risk of adequate maternal FA use
among fathers originating from low/middle-income
countries.
The strengths of our study included use of compre-
hensive data from population-based registries in Norway
that assures generalizability of our results, and registra-
tion of individual-level information on periconceptional
FA intake for all births in Norway since 1999 (except for
terminated pregnancies).
Our study had some limitations. Maternal FA intake
could have been misclassified; in the beginning of the
study period, FA users were underreported to the MBRN
[47]. Our results may therefore be somewhat weaker
than the true associations. Furthermore, we could not
adjust for pregnancy planning, maternal physical activity
or maternal use of alcohol [16, 18, 20–24], as these po-
tential confounders/covariates were not available in our
dataset. However, a recent longitudinal study during
2014 on men’s pregnancy planning comprising about
800 participants in Sweden, showed that 81% of the
pregnancies were planned and the level of paternal edu-
cation was positively associated with pregnancy planning
[48]. Moreover, data from 22,500 mothers in the MoBa
study with deliveries recorded in 2000–2003 showed that
78% of the mothers had planned their pregnancy [22].
However, MoBA is not entirely representative of the
Table 3 Relative risks (RRs) with 95% confidence intervals (95% CI) of adequate maternal periconceptional folic acid supplement use
(before and during pregnancy) by combining maternal and paternal education in 683,785 pregnancies, Norway, 1999–2010
Adequate folic acid use Unadjusted Adjusted a
Maternal education Paternal education Yes No RR* 95% CI RR* 95% CI
Compulsory education Compulsory education 2557 48,326 0.46 0.43–0.50 0.53 0.50–0.57
Intermediate education 4758 52,693 0.77 0.72–0.81 0.76 0.72–0.81
Tertiary education 1292 10,651 1.00 Reference 1.00 Reference
Missing information 208 4994
Intermediate education Compulsory education 5079 43,708 0.60 0.57–0.62 0.66 0.64–0.68
Intermediate education 18,055 116,378 0.77 0.75–0.79 0.81 0.79–0.83
Tertiary education 7477 35,269 1.00 Reference 1.00 Reference
Missing information 426 3928
Tertiary education Compulsory education 3805 17,985 0.70 0.67–0.72 0.75 0.73–0.77
Intermediate education 22,150 80,373 0.86 0.85–0.87 0.88 0.87–0.89
Tertiary education 42,541 126,896 1.00 Reference 1.00 Reference
Missing information 747 3539
Missing data (maternal education) 28,179 1771
aAdjusted for paternal age (< 20, 20–24, 25–29, 30–34, 35–39, 40+), year of childbirth (1999–2010 (continuous)), paternal country of origin (Norway, high income
countries, low/middle income countries), stratified by maternal education
*p values for interaction between maternal and paternal education were calculated by likelihood-ratio tests (unadjusted p value < 0.001; adjusted p value < 0.001)
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total pregnant population in Norway, since the partici-
pants are somewhat better educated, slightly older at de-
livery, and with a lower percentage of smokers than the
overall pregnant population.
Information about fathers was not available in 12,699
births (2% of all births in the study population) and were
excluded from the study population. They represent
births with fathers unreported by the pregnant woman
or fathers without identification number from the NR.
Among the excluded births (missing father information),
10% of the mothers had adequate periconceptional FA
supplementation (16% in the study population) with an
RR of 0.63 (95% CI 0.60–0.66) for adequate maternal FA
use comparing births with unregisterd fathers with
births having registered fathers.
Adjusting for maternal confounders (maternal age,
education, or country of origin) in our analysis reduced
the strength of the associations between paternal deter-
minants (age, education or country of origin) and ad-
equate maternal periconceptional FA use. This suggest
that paternal factors are important, but targeting mater-
nal demographic and socioeconomic conditions and
other factors related to low use is still important. How-
ever, our findings have implications for public health
practice. Recent research on men’s birth intentions has
shown that 63% of pregnancies were intended (wanted)
by the father [49]. Further, our study demonstrates the
importance of the partner’s impact on maternal repro-
ductive health and family planning through shared
decision-making.
Conclusions
In conclusion, our study supports the importance of fa-
ther’s prenatal role in their children’s health. In order to
improve maternal periconceptional FA supplementation
use, information and knowledge about the importance of
FA’s preventive potential needs to be directed to both
men and women. Furthermore, our findings show that
women having partners originating from low/middle-in-
come countries, partners at age < 30 and > 34 years, hav-
ing compulsory education only, and having occupations
other than “higher professional”, compared to “lower
professionals”, are particularly susceptible to low peri-
conceptional FA use. Therefore, campaigns for improved
FA supplementation use should focus particularly on
these groups.
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